{"title":"The Highest Quality Peptides","description":"","products":[{"product_id":"ghk-cu-50mg","title":"GHK-Cu 50mg","description":"\u003cp\u003e\u003cspan\u003eGHK-cu is a complex formed by a tripeptide and divalent copper ions (Cu⊃2;⁺). It regulates cellular activity through multiple mechanisms: stimulating fibroblast proliferation, promoting collagen, elastin, and glycosaminoglycan synthesis, and modulating extracellular matrix remodeling. It exhibits anti-inflammatory activity by inhibiting pro-inflammatory factor release and reducing tissue inflammatory responses. It also promotes angiogenesis, accelerates wound healing, and exerts antioxidant effects by scavenging reactive oxygen species. GHK-cu finds extensive application in dermatology for improving skin barrier function and reducing wrinkles. In wound healing research, its tissue regeneration properties are leveraged to accelerate skin wound recovery.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003eWhat is GHK-cu?\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003eGHK-cu is a complex formed by the binding of a tripeptide—composed of glycine (Gly), histidine (His), and lysine (Lys) linked by peptide bonds—to divalent copper ions (Cu⊃2;⁺). Within its chemical structure, the imidazole ring of the histidine residue forms a stable coordinate bond with the copper ion, creating a coordination compound with a specific spatial conformation and biological activity.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003cspan\u003eGHK - Cu Structure\u003c\/span\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cstrong\u003e\u003cimg\u003e\u003cimg alt=\"\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/90cda65b-f2a3-4cbc-a9fa-b8a95bfe9597.png?v=1782898124\"\u003e\u003c\/strong\u003e\n\u003cp\u003eSequence: Gly-His-Lys\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C\u003csub\u003e28\u003c\/sub\u003eH\u003csub\u003e46\u003c\/sub\u003eCuN\u003csub\u003e12\u003c\/sub\u003eO\u003csub\u003e8\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp\u003eMolecular Weight:  742.3g\/mol\u003c\/p\u003e\n\u003cp\u003eCAS Number: 130120-56-8\u003c\/p\u003e\n\u003cp\u003ePubChem CID: 9831891\u003c\/p\u003e\n\u003cp\u003eSynonyms: Bisprezatide copper；DL1TR6W6VM\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGHK - Cu Research\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the research background of GHK-cu?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the 1970s, American scientists investigating the effects of human plasma on tissues from different age groups made a keen observation. When plasma from young individuals was added to liver tissue from older individuals, the aged liver tissue began to efficiently produce specific proteins like that of young tissue. After in-depth analysis, in 1973, he successfully isolated GHK-Cu from human serum. This complex is formed by a tripeptide composed of glycine, histidine, and lysine tightly bound to a copper ion. Further research revealed that GHK-Cu naturally exists in human physiological processes within saliva, blood, and urine. Its concentration levels are closely linked to age: reaching approximately 200ng\/mL in the plasma of 20-year-olds, but sharply declining to around 80ng\/mL by age 60.\u003c\/p\u003e\n\u003cp\u003eSubsequent research continues to expand the boundaries of GHK-Cu understanding. In the early 1980s, scholars discovered that the human body releases GHK at injury sites, boldly hypothesizing its potential role as an early key signal for skin repair. Since then, extensive research has focused on GHK-Cu's role in tissue remodeling, particularly in skin regeneration. GHK-Cu stimulates the synthesis of collagen, elastin, and glycosaminoglycans while regulating the activity of metalloproteinases and their inhibitors. It exerts positive effects in anti-inflammation, antioxidant defense, and angiogenesis, gradually becoming a subject of research across multiple fields including biochemistry, dermatology, and regenerative medicine.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the mechanism of action for GHK-Cu?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePromoting Wound Healing\u003c\/p\u003e\n\u003cp\u003eCell Proliferation and Migration: GHK-Cu stimulates the proliferation and migration of various cells, including skin fibroblasts and endothelial cells. For instance, at skin wound sites, it accelerates the synthesis of extracellular matrix components like collagen and elastin by fibroblasts, providing structural support for wound healing. Simultaneously, it attracts endothelial cells to migrate toward the wound, promoting new blood vessel formation. This delivers ample nutrients and oxygen to the wound, accelerating the healing process\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eRegulation of Growth Factors: This complex modulates the expression and release of multiple growth factors, such as transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF). Taking VEGF as an example, GHK-Cu promotes its secretion, which in turn stimulates vascular endothelial cell proliferation and angiogenesis—critical processes for wound healing\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eAnti-inflammatory Effects\u003c\/p\u003e\n\u003cp\u003eInhibition of Inflammatory Mediators: GHK-Cu suppresses the production and release of multiple inflammatory mediators, including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). These mediators play key roles in inflammatory responses. By inhibiting their expression, GHK-Cu reduces the intensity and duration of inflammation, thereby alleviating tissue damage\u003csup\u003e\u003cspan\u003e \u003c\/span\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eModulation of Immune Cells: It also regulates immune cell function. By modulating macrophage polarization toward anti-inflammatory macrophages, it reduces the release of inflammatory mediators and promotes tissue repair\u003csup\u003e\u003cspan\u003e \u003c\/span\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eDNA Repair\u003c\/p\u003e\n\u003cp\u003eActivation of Repair Pathways: GHK-Cu activates intracellular DNA repair pathways. When cells are damaged by various endogenous or exogenous factors, they initiate a series of DNA repair mechanisms. GHK-Cu promotes the repair of damaged DNA by regulating the activity of related repair enzymes, such as DNA polymerase and ligase, thereby maintaining genomic stability\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eAntioxidant Protection: It possesses antioxidant capacity, reducing reactive oxygen species (ROS)-induced DNA damage. ROS can cause DNA strand breaks and base oxidation. By scavenging ROS, GHK-Cu indirectly protects DNA from damage, creating favorable conditions for DNA repair\u003csup\u003e\u003cspan\u003e \u003c\/span\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eRegulating Cellular Metabolism\u003c\/p\u003e\n\u003cp\u003ePromoting Energy Metabolism: Regarding cellular energy metabolism, GHK-Cu may influence mitochondrial function. Mitochondria serve as cellular powerhouses, and GHK-Cu may enhance cellular energy production efficiency by regulating the activity of mitochondrial-associated enzymes—such as those involved in the tricarboxylic acid cycle and oxidative phosphorylation—thereby meeting energy demands during cellular processes like growth and repair\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eRegulating Substance Synthesis: GHK-Cu also modulates the synthesis of crucial intracellular substances. As previously noted, it promotes the synthesis of extracellular matrix components like collagen and elastin. Additionally, it influences the synthesis and metabolism of intracellular substances such as proteins and lipids, thereby maintaining normal cellular physiological functions\u003csup\u003e\u003cspan\u003e \u003c\/span\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat are the applications of GHK-Cu?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWound Healing: GHK-Cu possesses the ability to promote wound healing. It stimulates angiogenesis, supplying ample nutrients and oxygen to the wound site, thereby accelerating tissue repair and regeneration. GHK-Cu also supports the function of dermal fibroblasts, promoting the synthesis of collagen, elastin, and glycosaminoglycans. This aids in constructing a healthy extracellular matrix and expedites the wound healing process. In Pickart L's study on skin injuries, treatment with GHK-Cu-containing formulations significantly accelerated wound healing speed and improved healing quality\u003csup\u003e\u003cspan\u003e \u003c\/span\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eAnti-inflammatory Effects: It mitigates inflammatory responses by inhibiting inflammation-related signaling pathways. In both a lipopolysaccharide (LPS)-induced acute lung injury (ALI) mouse model and in vitro experiments with RAW 264.7 macrophages, GHK-Cu treatment reduced reactive oxygen species (ROS) production, increased superoxide dismutase (SOD) activity, and decreased the generation of inflammatory mediators such as tumor necrosis factor -α (TNF-α) and interleukin-6 (IL-6), achieved by inhibiting NF-κB p65 and p38 MAPK signaling pathways. Thus, GHK-Cu demonstrates therapeutic potential for inflammation-related diseases like ALI\/Acute Respiratory Distress Syndrome (ARDS)\u003csup\u003e[3]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eCellular Protection: Exhibits multiple cellular protective effects. In chronic obstructive pulmonary disease (COPD), it protects and repairs lung tissue while restoring COPD fibroblast function. It also inhibits molecules like NFκB, which are believed to accelerate aging diseases, demonstrating anti-aging potential. Additionally, it exhibits anti-anxiety, analgesic, and anti-aggression activities, and activates cellular cleanup functions via the proteasome system, providing comprehensive cellular protection\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[2]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e.\u003c\/p\u003e\n\u003cp\u003eDNA Repair: GHK-Cu participates in intracellular DNA repair processes, helping maintain genomic stability and reducing cellular pathology and aging issues caused by accumulated DNA damage. This supports the prevention and treatment of DNA damage-related diseases\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs an endogenous tripeptide-copper complex, GHK-Cu exhibits multidimensional biological activity. By activating signaling pathways such as PI3K\/Akt and MAPK\/ERK, it promotes fibroblast proliferation, angiogenesis, and extracellular matrix synthesis, playing a crucial role in wound healing. It also exhibits anti-inflammatory, antioxidant, and immunomodulatory functions, alleviating tissue inflammatory damage and aiding in trauma repair and inflammatory disease intervention.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAbout The Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe above-mentioned materials are all researched, edited and compiled by Cocer Peptides.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eScientific Journal Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLoren Pickart was a renowned biochemist and founder of Skin Biology Inc., specializing in the study of copper peptides and their applications in skin health and aging. He discovered the copper peptide GHK-Cu in 1973 during his doctoral research at the University of California, San Francisco. This discovery led to the development of skin rejuvenating copper peptides and the establishment of Skin Biology Inc. in 1994. His work has significantly contributed to the understanding of skin biology and the development of anti-aging treatments. Pickart's research continues to influence the field of dermatology and regenerative medicine. Loren Pickart is listed in the reference of citation [2].\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRelevant Citations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e[1] Sun L, Li A, Hu Y, Li Y, Shang L, Zhang L. Self‐Assembled Fluorescent and Antibacterial GHK‐Cu Nanoparticles for Wound Healing Applications. Particle \u0026amp; Particle Systems Characterization 2019; 36: 1800420.DOI: 10.1002\/ppsc.201800420.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[2] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences 2018; 19. https:\/\/api.semanticscholar.org\/CorpusID:51609461.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[3] Park JR, Lee H, Kim SI, Yang SR. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung  injury in mice. Oncotarget 2016; 7(36): 58405-58417.DOI: 10.18632\/oncotarget.11168.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53266920243424,"sku":null,"price":59.9,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/94470f94-0de5-4e80-806f-ae6e5dfbd3e0.png?v=1782898014"},{"product_id":"tirzepatid-10mg","title":"Tirzepatid 10mg","description":"\u003cp\u003e\u003cspan\u003eTirzepatid, a synthetic peptide, works by activating GLP-1 and GIP receptors to modulate blood glucose, boost insulin secretion, inhibit glucagon release, and improve insulin sensitivity. It further slows gastric emptying, enhances satiety, curbs food intake, reduces weight, raises adiponectin levels, and optimizes lipid metabolism. Studies indicate it outperforms single GLP-1 agonists in HbA1c reduction and weight loss, with positive effects on blood pressure and lipids, as well as potential cardiovascular benefits, making it a novel therapy for type 2 diabetes and obesity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cstrong\u003eTirzepatid Overview\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eTirzepatid is a synthetic polypeptide drug and the first dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This drug can regulate blood glucose levels. Specifically, activating the glucagon-like peptide-1 receptor can promote insulin secretion and inhibit the release of glucagon; while activating the glucose-dependent insulinotropic polypeptide receptor can enhance insulin sensitivity and secretion ability.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn addition to regulating blood glucose, it can also delay the process of gastric emptying, increase satiety, thereby reducing food intake and facilitating weight loss. Moreover, it can increase the level of adiponectin, thus improving insulin sensitivity and lipid metabolism.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eThe results of clinical trials show that in terms of blood glucose control, Tirzepatid has a better effect compared with single glucagon-like peptide-1 agonists and can significantly reduce the level of glycated hemoglobin (HbA1c). It also has a remarkable effect on weight loss, with an average weight loss of more than 20%, so it can also be used for the treatment of obesity.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eThe once-weekly injection regimen improves patients' medication compliance, and it has relatively few side effects. At the same time, it also has a positive impact on blood pressure and blood lipid conditions, demonstrating potential cardioprotective effects.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatid Structure\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/c0777290-d819-4f2d-8287-7dbfdd739ed6.png?v=1782899748\" alt=\"\"\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSequence: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-C20-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH\u003csub\u003e2\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C\u003csub\u003e225\u003c\/sub\u003eH\u003csub\u003e348\u003c\/sub\u003eN\u003csub\u003e48\u003c\/sub\u003eO\u003csub\u003e68\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp\u003eMolecular Weight: 4813 g\/mol\u003c\/p\u003e\n\u003cp\u003eCAS Number: 2023788-19-2\u003c\/p\u003e\n\u003cp\u003ePubChem CID: 163285897\u003c\/p\u003e\n\u003cp\u003eSynonyms: Zepbound; Mounjaro\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatid Research\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the research background of Tirzepatid?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTirzepatid is a synthetic polypeptide drug. Its research and development stem from a deep understanding of the limitations of existing GLP-1 receptor agonists in the treatment of type 2 diabetes and obesity at that time. Although GLP-1 receptor agonists have shown excellent performance in blood glucose control and weight loss, scientists found that their activation of the GIP receptor is relatively weak, which limits the efficacy of the drugs to a certain extent. Therefore, the research and development team was committed to developing a new drug that can activate both the GIPR and GLP-1R simultaneously to achieve more comprehensive and effective blood glucose control and weight management\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eDuring the research and development process of Tirzepatid, scientists carried out a large number of basic research and clinical trials. In the preclinical research stage, animal experiments were used to thoroughly evaluate the pharmacodynamic properties of Tirzepatid. The results confirmed its potential in blood glucose control and weight loss, laying the foundation for subsequent clinical trials. Subsequently, Tirzepatid entered the clinical trial stage, including phases I, II, and III. Phase I mainly evaluated the safety, tolerability, and pharmacokinetic properties of the drug, and the results showed good safety and tolerability. Phase II further explored the efficacy and safety of different doses in patients with type 2 diabetes, preliminarily determining the effective dose range. The key phase III clinical trials, such as the SURPASS series of studies, involved a large number of patients with type 2 diabetes. The results showed that Tirzepatid was significantly superior to existing GLP-1 receptor agonists, such as Semaglutid, in reducing blood glucose and weight, providing strong evidence for the marketing application\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eTirzepatid is a polypeptide composed of 39 amino acids, and its structure has been modified to improve its stability and pharmacodynamics. Its unique structural design enables it to integrate the effects of two incretins, GIP and GLP-1, into a single molecule, activating the hormone receptors involved in blood glucose control through a dual mechanism. Specifically, on the one hand, it acts on the pancreas to promote insulin secretion and inhibit glucagon release to lower blood glucose; on the other hand, it acts on the central nervous system, delaying gastric emptying, increasing satiety, reducing appetite and food intake, and achieving weight management. This dual mechanism gives Tirzepatid unique advantages in the treatment of type 2 diabetes and obesity, providing patients with a more comprehensive treatment option\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the mechanism of action of Tirzepatid?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatid lowers blood glucose through the following multiple mechanisms:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eActivation of GLP-1 Receptors: Tirzepatid binds to the GLP-1 receptors on pancreatic beta cells, mimicking the action of natural GLP-1. GLP-1 is a hormone produced by the intestine that is crucial for maintaining glucose homeostasis. It can promote insulin synthesis, secretion, and glucose sensing, and reduce glucagon secretion to promote satiety and suppress appetite. In patients with type 2 diabetes, insufficient insulin secretion or reduced cellular sensitivity to insulin leads to elevated blood glucose. Tirzepatid increases insulin secretion by activating GLP-1 receptors, improving blood glucose control. At the same time, the activation of GLP-1 receptors can also inhibit the release of glucagon, further reducing the sources of blood glucose and contributing to blood glucose control\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eActivation of GIP Receptors: Tirzepatid acts on GIP receptors, and its activation can enhance insulin sensitivity and secretion. GIP receptors are mainly present in tissues such as pancreatic beta cells. After activation, through intracellular signal pathway transduction, insulin secretion is increased, and the cell's responsiveness to insulin is enhanced, reducing blood glucose more effectively\u003csup\u003e[2]\u003c\/sup\u003e. This dual receptor agonist effect makes Tirzepatid more effective than single GLP-1 receptor agonists in promoting insulin secretion and inhibiting glucagon release\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eDelaying Gastric Emptying and Increasing Satiety: Tirzepatid can delay gastric emptying, prolonging the residence time of food in the stomach, slowing down the absorption rate of nutrients, and preventing a sharp rise in postprandial blood glucose. Its effect on gastric emptying is comparable to that of GLP-1 receptor agonists. At the same time, it acts on the central nervous system, increasing satiety, reducing appetite and food intake, which is especially suitable for the obesity problem often accompanied by patients with type 2 diabetes, helping to improve insulin resistance and the overall metabolic condition\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eImproving Insulin Sensitivity and Lipid Metabolism: Tirzepatid can increase the level of adiponectin, an adipocytokine related to insulin sensitivity, helping to improve insulin sensitivity, enabling cells to more effectively uptake and utilize glucose, and reducing blood glucose (Anonymous, 2023). In addition, it can also improve the lipid profile, having a potential protective effect on cardiovascular health. It has been proven to be able to improve blood pressure, reduce LDL cholesterol and triglycerides\u003csup\u003e[3]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/d878bd4b-7b30-49df-a05c-fe390c145ead.png?v=1782899837\" alt=\"\"\u003e\u003cimg\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSource: PubMed\u003c\/span\u003e\u003csup\u003e[5]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat are the related studies?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEfficacy on Weight Management in Patients with Obesity and Type 2 Diabetes\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNumerous clinical studies have confirmed that Tirzepatid has a significant weight loss effect. In the \"SURMOUNT-2\" study, this phase 3, double-blind, randomized, placebo-controlled trial was conducted in seven countries. Adults (aged ≥ 18 years) with a BMI of 27 kg\/m² or higher and HbA₁c of 7 - 10% were enrolled and randomly assigned to receive once-weekly subcutaneous injection of Tirzepatid (10 mg or 15 mg) or placebo for 72 weeks. The results showed that at week 72, the percentage of weight loss in the Tirzepatid 10 mg and 15 mg groups was -12.8% and -14.7% respectively, compared with -3.2% in the placebo group. The estimated treatment differences of Tirzepatid 10 mg and 15 mg compared with the placebo were -9.6 percentage points and -11.6 percentage points respectively, which were statistically significant (p \u0026lt; 0.0001). In addition, more patients receiving Tirzepatid treatment reached the threshold of a 5% or greater weight loss (79 - 83% vs 32%) (Garvey W T, 2023). In this study, the average baseline weight was 100.7 kg, the BMI was 36.1 kg\/m², and the HbA₁c was 8.02%. After 72 weeks of treatment, Tirzepatid not only significantly reduced body weight but also had a positive effect on blood glucose control \u003csup\u003e[4]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImprovement of Diabetic Neuropathy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStudies have pointed out that GLP1-RAs can reduce the risk of dementia in patients with type 2 diabetes by improving memory, learning, and overcoming cognitive impairment. As a dual GIP-RA\/GLP-1RA, in the neuroblastoma cell line (SHSY5Y), research has found that Tirzepatid has an impact on markers of neuronal growth (CREB and BDNF), apoptosis (BAX\/Bcl2 ratio), differentiation (pAkt, MAP2, GAP43, and AGBL4), and insulin resistance (GLUT1, GLUT4, GLUT3, and SORBS1). The results emphasize the role of Tirzepatid in activating the pAkt\/CREB\/BDNF pathway and downstream signaling cascades and its neuroprotective efficacy, indicating that it can counteract the effects associated with hyperglycemia and insulin resistance at the neuronal level. Therefore, Tirzepatid can improve the neurodegeneration caused by hyperglycemia and overcome neuronal insulin resistance, providing new insights into the improvement of diabetes-related neuropathy \u003csup\u003e[5]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eResearch Progress in the Treatment of Type 2 Diabetes\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs a new type of hypoglycemic drug, Tirzepatid has become the first dual GIP\/GLP-1R agonist approved for the treatment of diabetes in the United States. A number of large-scale clinical trials have confirmed its significant blood glucose lowering and weight loss effects, and it has the potential in cardiovascular protection. The concept of synthetic peptides has opened up many unknown possibilities for Tirzepatid. Ongoing trials (NCT04166773) and evidence suggest that it is a promising drug in the fields of non-alcoholic fatty liver disease (NAFLD), renal and neuroprotection \u003csup\u003e[6]\u003c\/sup\u003e(Ma Z, 2023).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eLong-term Impact of Tirzepatid on Cardiovascular Health\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTirzepatid may reduce the risk of cardiovascular diseases by promoting weight loss. A study examined the impact of Tirzepatid on obesity and cardiovascular disease events in American adults\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[7]\u003c\/sup\u003e. The study found that among American adults eligible for Tirzepatid treatment, after treatment with 15 mg of Tirzepatid, an estimated 70.6% and 56.7% of adults lost ≥ 15% and ≥ 20% of their body weight respectively, which means a 58.8% reduction in the number of obese people. Among those without cardiovascular disease, the estimated 10-year cardiovascular disease risk decreased from 10.1% \"before treatment\" to 7.7% \"after treatment\", with an absolute risk reduction of 2.4% and a relative risk reduction of 23.6%, preventing 2 million cardiovascular disease events.\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn conclusion, Tirzepatid is a new type of dual agonist of GIP and GLP-1 receptors, which is of great significance in the treatment of type 2 diabetes and obesity. It can more effectively promote insulin secretion, inhibit glucagon secretion, precisely regulate blood glucose, reduce the risk of complications, improve the function of pancreatic beta cells, delay the progression of diabetes, and has a cardioprotective effect. In the treatment of obesity, it can effectively reduce food intake, lower appetite, increase satiety, help obese patients lose weight, and reduce the risk of obesity-related complications. It can also improve insulin resistance and lipid metabolism. In addition, it shows potential in the treatment of metabolic abnormal related diseases such as non-alcoholic steatohepatitis, sleep apnea syndrome, and heart failure, and can simultaneously improve multiple metabolic indicators, providing a more comprehensive treatment plan. Its once-weekly injection method is convenient to use and can improve patients' treatment compliance. By effectively controlling blood glucose and weight and reducing the risk of complications, it can significantly improve patients' physical condition, enhance their daily activity ability and quality of life, increase their confidence in disease control, reduce their psychological burden, and improve their social adaptability.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cstrong\u003eAbout The Author\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eThe above-mentioned materials are all researched, edited and compiled by Cocer Peptides.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eScientific Journal Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDr. William T. Garvey is a distinguished scholar and researcher affiliated with multiple prestigious institutions, including the University of Alabama at Birmingham, Aston University, and the Birmingham Veterans Affairs Medical Center. His academic background and professional experience span a wide range of disciplines within the medical and scientific fields. Dr. Garvey has made significant contributions to the fields of endocrinology and metabolism, nutrition and dietetics, biochemistry and molecular biology, as well as general and internal medicine, with a particular focus on the cardiovascular system and cardiology. His work has been widely recognized and honored, notably being named a Highly Cited Researcher in the Cross-Field category for both 2023 and 2024, reflecting the substantial impact and influence of his research on the broader scientific community.\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDr. Garvey's research interests and expertise extend to various aspects of metabolic diseases and their management. He has been actively involved in studying diabetes mellitus, obesity, and their associated complications, aiming to uncover novel therapeutic strategies and improve patient outcomes. His work encompasses basic scientific research, clinical trials, and translational studies, bridging the gap between laboratory findings and real-world medical applications. Through his extensive research, Dr. Garvey has contributed to a deeper understanding of the underlying mechanisms of metabolic disorders and has helped shape clinical guidelines and treatment protocols in the field of endocrinology and metabolism. Dr. William T. Garvey is listed in the reference of citation \u003c\/span\u003e\u003csup\u003e[4\u003c\/sup\u003e\u003cspan\u003e].\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cstrong\u003eRelevant Citations\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e[1] Nowak M, Nowak W, Grzeszczak W. Tirzepatid - a dual GIP\/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes[J]. Endokrynologia Polska, 2022,73(4):745-755.DOI:10.5603\/EP.a2022.0029.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[2] Anonymous. Tirzepatid: A Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus: Erratum.[J]. American Journal of Therapeutics, 2023,30(3):e311.DOI:10.1097\/MJT.0000000000001634.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[3] Forzano I, Varzideh F, Avvisato R, et al. Tirzepatid: A Systematic Update[J]. International Journal of Molecular Sciences, 2022,23(23).DOI:10.3390\/ijms232314631.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[4] Garvey W T, Frias J P, Jastreboff A M, et al. Tirzepatid once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2023,402(10402):613-626.DOI:10.1016\/S0140-6736(23)01200-X.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[5] Fontanella R A, Ghosh P, Pesapane A, et al. Tirzepatid prevents neurodegeneration through multiple molecular pathways[J]. Journal of Translational Medicine, 2024,22(1).DOI:10.1186\/s12967-024-04927-z.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[6] Ma Z, Jin K, Yue M, et al. Research Progress on the GIP\/GLP-1 Receptor Coagonist Tirzepatid, a Rising Star in Type 2 Diabetes[J]. Journal of Diabetes Research, 2023,2023.DOI:10.1155\/2023\/5891532.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[7] Wong N D, Karthikeyan H, Fan W. US Population Eligibility and Estimated Impact of Tirzepatid Treatment on Obesity Prevalence and Cardiovascular Disease Events[J]. Cardiovascular Drugs and Therapy, 2024.DOI:10.1007\/s10557-024-07583-z.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267655327968,"sku":null,"price":110.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/4d9f0a3e-232b-499f-a3c7-23693f1e67f8.png?v=1782899999"},{"product_id":"retatrutid-30mg","title":"Retatrutid 30mg","description":"\u003cp\u003e\u003cspan\u003eRetatrutid is a novel peptide drug and triple receptor agonist acting on GLP-1, GIP, and glucagon receptors. It aids in weight reduction by regulating appetite, enhancing satiety, and increasing energy expenditure. Retatrutid also improves cardiovascular-metabolic risk markers such as blood pressure, HbA1c, fasting glucose, insulin, cholesterol, and triglycerides. Furthermore, it benefits non-alcoholic fatty liver disease patients by normalizing liver fat. Unlike single or dual agonists, Retatrutid's triple action mechanism offers more extensive metabolic benefits, making it more effective for weight loss, liver fat reduction, and blood sugar normalization. Retatrutid is a promising new treatment option for obese and type 2 diabetic patients, especially those unresponsive to current treatments.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003cspan\u003eRetatrutid  Overview\u003c\/span\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cp\u003eRetatrutid is a novel peptide drug. As a triple receptor agonist, it acts on the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. It helps individuals lose weight by comprehensively regulating appetite, enhancing satiety, suppressing hunger, and increasing energy expenditure.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn addition, Retatrutid can also improve multiple cardiometabolic risk indicators, such as blood pressure, glycated hemoglobin, fasting blood glucose, insulin, total cholesterol, low-density lipoprotein cholesterol, and triglycerides. It also has a positive effect on patients with non-alcoholic fatty liver disease, enabling the liver fat content of most participants to return to normal.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eCompared with single or dual agonists, Retatrutid regulates blood glucose, body weight, etc. from multiple dimensions by simultaneously activating the three receptors of GLP-1, GIP, and glucagon (GCG). Theoretically, it can more comprehensively improve metabolic disorders and has unique advantages in aspects such as weight loss, reduction of hepatic steatosis, and normalization of blood glucose levels.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eThe synergistic action of multiple receptors of Retatrutid makes it more effective than existing GLP-1 receptor agonists or dual receptor agonists in regulating metabolism and controlling body weight, providing new treatment options for patients with obesity and type 2 diabetes mellitus.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eRetatrutid  Structure\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/993024f9-25ff-4e7a-b6b3-e5e1411fd322.png?v=1782900264\" alt=\"\"\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSequence: YA⊃1;QGTFTSDYSI-L⊃2;LDKK⁴AQA⊃1;AFIEYLLEGGPSSGAPPPS⊃3;\u003c\/p\u003e\n\u003cp\u003eMolecular Formula:\u003cspan\u003e \u003c\/span\u003e\u003ca name=\"_Hlk193139181\"\u003e\u003c\/a\u003eC\u003csub\u003e221\u003c\/sub\u003eH\u003csub\u003e342\u003c\/sub\u003eN\u003csub\u003e46\u003c\/sub\u003eO\u003csub\u003e68\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp\u003eMolecular Weight:\u003ca name=\"_Hlk193139215\"\u003e\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003e4731 g\/mol\u003c\/p\u003e\n\u003cp\u003eCAS Number: 2381089-83-2\u003c\/p\u003e\n\u003cp\u003ePubChem CID: 171390338\u003c\/p\u003e\n\u003cp\u003eSynonyms：LY3437943\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutid  Research\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the research background of Retatrutid?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eObesity has become one of the prominent public health challenges in contemporary society. It can give rise to numerous health problems such as type 2 diabetes mellitus, cardiovascular diseases, hypertension, dyslipidemia, and non-alcoholic fatty liver disease. With the continuous increase in the incidence of obesity, there is an increasingly urgent need for new therapies that can effectively manage body weight and improve health conditions\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[1]\u003c\/sup\u003e. Although lifestyle interventions, such as increased physical activity and dietary control, are the core measures for weight mnagement, it is extremely difficult for many adult obese patients to maintain long-term weight loss.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eRetatrutid, as a novel triple receptor agonist, can act on the glucagon-like peptide-1 receptor (\u003c\/p\u003e\n\u003cp\u003eGLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This multi-receptor mechanism of action endows it with significant advantages in the field of weight loss. Compared with weight loss drugs that act on only a single receptor, Retatrutid can more comprehensively regulate the body's metabolic processes\u003csup\u003e[1]\u003c\/sup\u003e. Retatrutid achieves weight loss by regulating multiple hormone receptors, not only showing remarkable efficacy but also having relatively mild gastrointestinal side effects. In addition, as a triple receptor agonist, Retatrutid has a more powerful weight loss effect and a wider range of applicable populations compared with other new weight loss drugs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is Retatrutid?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRetatrutid is a novel long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is modified and optimized based on the structure of natural GLP-1, and it can specifically bind to and activate the GLP-1 receptor, exerting physiological functions similar to those of natural GLP-1, such as promoting insulin secretion, inhibiting glucagon secretion, delaying gastric emptying, reducing appetite, etc. It has broad application prospects in the treatment of diabetes and weight management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eWhat is the mechanism of action of Retatrutid?\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe mechanism of action of Retatrutid stems from its agonistic effects on multiple receptors. Firstly, its agonistic effect on the glucagon-like peptide-1 receptor (GLP-1R) can increase insulin secretion, inhibit glucagon secretion, lower blood glucose levels, and at the same time delay gastric emptying, increase satiety, and reduce food intake\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[2]\u003c\/sup\u003e. Secondly, its agonistic effect on the glucose-dependent insulinotropic polypeptide receptor (GIPR) can promote insulin secretion, enhance glucose utilization, and affect fat metabolism, inhibiting lipolysis and promoting fat synthesis\u003csup\u003e[2]\u003c\/sup\u003e. Moreover, the agonistic effect of Retatrutid on the glucagon receptor (GCGR) usually promotes glycogenolysis and gluconeogenesis in the liver, increasing blood glucose levels. However, under the action of Retatrutid, this glucose-raising effect is offset by the effects of the other two receptors, while promoting lipolysis and reducing fat accumulation\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[2]\u003c\/sup\u003e. This multi-target mode of action may be more effective in treating obesity than single receptor agonists.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eBy simultaneously activating these three receptors, Retatrutid can exert a variety of metabolic regulatory effects and produce therapeutic effects on obesity and related diseases. In terms of regulating blood glucose levels, since the activation of GLP-1R and GIPR promotes insulin secretion and inhibits glucagon secretion, and the activation of GCGR is offset by the effects of the other two receptors, Retatrutid can effectively regulate blood glucose levels, which is of great significance for the treatment of type 2 diabetes mellitus\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[1, 2]\u003c\/sup\u003e. In terms of reducing fat accumulation, the activation of GCGR promotes lipolysis and reduces fat accumulation, while the activation of GLP-1R increases satiety and reduces food intake, further reducing fat synthesis\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[1]\u003c\/sup\u003e. In addition, Retatrutid also has an improving effect on non-alcoholic fatty liver disease. It can reduce the fat content in the liver and improve liver function.\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/73884d4c-7d0d-4d3b-ba05-ca8b634d9719.png?v=1782900321\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eHbA1c, bodyweight, blood pressure, and lipids Data are least-squares means (with error bars showing SEs) from the efficacy analysis set, unless otherwise noted.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eSource:PubMed\u003csup\u003e[4]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003csup\u003e\u003cstrong\u003eIn what aspects does Retatrutid show its effects?\u003c\/strong\u003e\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003csup\u003e\u003cstrong\u003eRetatrutid exhibits significant effects in multiple aspects\u003c\/strong\u003e\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003eSignificant weight loss effect: Retatrutid has demonstrated significant weight loss effects in multiple clinical trials. For example, in a clinical study involving 338 adults (Jastreboff A M M, 2023), patients treated with different doses of Retatrutid experienced significant weight loss at 48 weeks. Among them, patients in the 12mg dose group lost 24.2% of their body weight, and a high proportion of patients achieved weight loss to varying degrees. For instance, among patients receiving 4mg, 8mg, and 12mg doses, 92%, 100%, and 100% of the patients, respectively, lost 5% or more of their body weight. In another study\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[3]\u003c\/sup\u003e, two randomized controlled trials involving 353 patients with type 2 diabetes mellitus showed that compared with the placebo, Retatrutid could significantly reduce the body weight of patients by 11.89kg, and also reduce glycated hemoglobin (HbA1C). In addition, in trials of adult patients with obesity without diabetes, Retatrutid caused a 24.2% weight loss in patients, and 83% of the patients lost 15% or more of their body weight at 48 weeks. These results indicate that Retatrutid has great potential in weight loss.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of type 2 diabetes mellitus: Retatrutid also shows certain potential in the treatment of type 2 diabetes mellitus. In some clinical trials, Retatrutid has shown a reduction in glycated hemoglobin (HbA1c) and dose-dependent weight loss. For example, in one study, in patients with type 2 diabetes mellitus, Retatrutid demonstrated significant blood glucose control effects. Compared with the placebo, glycated hemoglobin decreased by 1.64%\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[3]\u003c\/sup\u003e. Additionally, in a randomized, double-blind, placebo and active-controlled parallel-group phase 2 trial, animal models with type 2 diabetes mellitus, after receiving Retatrutid treatment, showed a significant decrease in glycated hemoglobin levels, and their body weight also decreased in a dose-dependent manner\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[4]\u003c\/sup\u003e. This can be attributed to the comprehensive effects of the drug on GLP-1, GCGR, and GIPR, which improve glucose metabolism and energy balance.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eImprovement of cardiovascular risk factors: Retatrutid can not only reduce body weight but also improve cardiovascular risk factors, such as the serum lipid profile and glycated hemoglobin levels. This indicates a close pathophysiological link between obesity and cardiovascular diseases, and Retatrutid may improve the cardiovascular health of obese patients through multiple pathways. For example, reducing non-HDL-C, apoB, and LDLP levels can reduce the risk of atherosclerosis; reducing glycated hemoglobin levels can improve blood glucose control in patients with diabetes, thereby reducing the risk of cardiovascular complications\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[3, 5, 6]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of non-alcoholic fatty liver disease (NAFLD): Retatrutid is a novel triple receptor agonist peptide that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Studies have shown that Retatrutid has the potential to treat non-alcoholic fatty liver disease. In one study, a randomized, double-blind, placebo-controlled trial was conducted for 48 weeks on participants with metabolic dysfunction-associated fatty liver disease and a liver fat content of ≥10%. The results showed that at 24 weeks, the average relative changes in liver fat from the baseline in participants treated with different doses of Retatrutid (1mg, 4mg, 8mg, and 12mg) were -42.9%, -57.0%, -81.4%, and -82.4%, respectively, while that in the placebo group was +0.3%\u003csup\u003e[7]\u003c\/sup\u003e. This indicates that Retatrutid may have a significant therapeutic effect on non-alcoholic fatty liver disease.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn conclusion, as a novel triple receptor agonist, Retatrutid shows great potential in the treatment of obesity and related diseases. It can regulate human metabolism from multiple dimensions by activating the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor, improving blood glucose control, reducing body weight, and regulating lipid metabolism. The emergence of Retatrutid has brought new treatment options for patients with obesity, type 2 diabetes mellitus, etc. It is expected to break through the limitations of traditional single receptor agonist drugs, provide a more powerful weapon for solving the increasingly serious problems of obesity and metabolic diseases, promote the further development of related medical fields, improve the quality of life of patients, and reduce the social medical burden.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAbout The Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe above-mentioned materials are all researched, edited and compiled by Cocer Peptides.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eScientific Journal Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRosenstock J is a highly influential scholar in the medical field, closely collaborating with institutions such as the University of Texas Southwestern Medical Center and the University of Texas Dallas. He also conducts research at centers like the Canadian VIGOUR Center and Veloc Clin Res Ctr Med City. \u003c\/p\u003e\n\u003cp\u003e \u003cspan\u003eHis research spans endocrinology and metabolism, cardiovascular system and cardiology, pharmacology, and experimental medicine, with a focus on diabetes, obesity, and related treatments and drug development. J Rosenstock has achieved significant success in clinical medicine, being named a Highly Cited Researcher from 2017 to 2024. This highlights the high impact and broad recognition of his work. Through collaboration with multiple research institutions, he has successfully translated basic research findings into clinical applications, benefiting patients with metabolic and cardiovascular diseases and advancing medical science. Rosenstock J is listed in the reference of citation [4].\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cstrong\u003eRelevant Citations\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e[1]    Kaur M, Misra S. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity[J]. European Journal of Clinical Pharmacology, 2024,80(5):669-676.DOI:10.1007\/s00228-024-03646-0.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[2]    Jastreboff A M, Kaplan L M, Frias J P, et al. Triple-Hormone-Receptor Agonist Retatrutid for Obesity - A Phase 2 Trial[J]. New England Journal of Medicine, 2023,389(6):514-526.DOI:10.1056\/NEJMoa2301972.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[3]    Lopez D C, Pajimna J T, Milan M D, et al. 7792 Efficacy of Retatrutid for Weight Reduction and Its Cardiometabolic Effects Among Adults: A Systematic Review and Meta-Analysis[J]. Journal of the Endocrine Society, 2024,8(1):163-749.DOI:10.1210\/jendso\/bvae163.749.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[4]   Rosenstock J, Frias J, Jastreboff A M, et al. Retatrutid, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA[J]. Lancet, 2023,402(10401):529-544.DOI:10.1016\/S0140-6736(23)01053-X.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[5]    Nicholls S, Pirro V, Lin Y, et al. Triple-hormone receptor agonist retatrutide significantly improves lipoprotein and apolipoprotein profiles in participants with obesity or overweight[J]. European Heart Journal, 2024,45.DOI:10.1093\/eurheartj\/ehae666.1501.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[6]    Ray A. Retatrutid: a triple incretin receptor agonist for obesity management[J]. Expert Opinion On Investigational Drugs, 2023,32(11):1003-1008.DOI:10.1080\/13543784.2023.2276754.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[7]    Sanyal A J, Kaplan L M, Frias J P, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial[J]. Nature Medicine, 2024,30(7):2037-2048.DOI:10.1038\/s41591-024-03018-2.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267670860000,"sku":null,"price":430.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/60d24840-576b-44ea-a0aa-e217d2550b34.png?v=1782900446"},{"product_id":"retatrutid-40mg","title":"Retatrutid 40mg","description":"\u003cp\u003e\u003cspan\u003eRetatrutid is a peptide acting as a triple receptor agonist for GLP-1 receptors (GLP-1R), GIP receptors (GIPR), and glucagon receptors (GCGR). It enhances insulin secretion by activating GLP-1R, inhibits glucagon release, delays gastric emptying, and increases satiety; activates GIPR to enhance insulin sensitivity and regulate lipid metabolism; activates GCGR to promote energy expenditure, inhibit hepatic gluconeogenesis, and reduce hepatic fat deposition. This multi-target synergistic action makes it superior to traditional single-target GLP-1 drugs in lowering blood glucose, reducing body weight, and improving hepatic fat deposition.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003eWhat is Retatrutid?\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003eRetatrutid is a peptide drug acting as a triple agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR), targeting conditions such as obesity and type 2 diabetes.\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003cspan\u003eRetatrutid Structure\u003c\/span\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cstrong\u003e\u003cspan\u003e\u003cimg alt=\"\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/993024f9-25ff-4e7a-b6b3-e5e1411fd322.png?v=1782900264\"\u003e\u003c\/span\u003e\u003c\/strong\u003e\n\u003cp\u003eSequence: YA⊃1;QGTFTSDYSI-L⊃2;LDKK⁴AQA⊃1;AFIEYLLEGGPSSGAPPPS⊃3;\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C\u003csub\u003e221\u003c\/sub\u003eH\u003csub\u003e342\u003c\/sub\u003eN\u003csub\u003e46\u003c\/sub\u003eO\u003csub\u003e68\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp\u003eMolecular Weight: 4731 g\/mol\u003c\/p\u003e\n\u003cp\u003eCAS Number: 2381089-83-2\u003c\/p\u003e\n\u003cp\u003ePubChem CID: 171390338\u003c\/p\u003e\n\u003cp\u003eSynonyms：LY3437943\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutid Research\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the research background for Retatrutid?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe global prevalence of obesity and type 2 diabetes continues to rise, posing a significant public health challenge. Existing single- or dual-target drugs have limitations in efficacy and safety. Based on the theory of multi-target synergistic regulation via the gastrointestinal insulin axis, research has revealed complementary roles of GLP-1, GIP, and glucagon in metabolic regulation, providing a theoretical foundation for developing multi-receptor agonists.\u003c\/p\u003e\n\u003cp\u003eBuilding on prior dual-target drug development experience, researchers designed and optimized Retatrutid based on the structural characteristics and signaling mechanisms of these triple receptors. By simultaneously activating GLP-1R, GIPR, and GCGR, it achieves more potent glycemic control and weight reduction.\u003c\/p\u003e\n\u003cp\u003eWhat is the mechanism of action for Retatrutid?\u003c\/p\u003e\n\u003cp\u003eReceptor Agonism\u003c\/p\u003e\n\u003cp\u003eRetatrutid functions as a triple receptor agonist targeting GLP-1, GCGR, and GIP receptors\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eGLP-1 receptor agonism: GLP-1 is an incretin hormone secreted by intestinal L cells. Upon binding to GLP-1 receptors, Retatrutid promotes insulin secretion in a glucose-concentration-dependent manner. During hyperglycemia, Retatrutid binds to GLP-1 receptors, activating downstream signaling pathways that prompt pancreatic β-cells to secrete insulin and lower blood glucose levels. It also inhibits glucagon secretion and reduces hepatic glucose output, further stabilizing blood glucose. GLP-1 receptor agonism also delays gastric emptying, increases satiety, and reduces food intake, aiding in weight management\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eGCGR receptor agonism: Glucagon typically acts during hypoglycemia to elevate blood glucose levels. Retatrutid's agonist action on GCGR is complex. In adipose tissue, it promotes lipolysis and increases fatty acid oxidation, thereby enhancing energy expenditure. In the liver, moderate GCGR agonism may regulate processes like gluconeogenesis, optimizing hepatic metabolic function. This prevents excessive gluconeogenesis from causing hyperglycemia while maintaining sufficient blood glucose stability to meet the body's energy demands\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eGIP receptor agonism: GIP, another incretin hormone, is secreted by K cells in the duodenum and jejunum after meals. Retatrutid's GIP receptor agonism enhances insulin secretion, synergizing with GLP-1 to improve glucose regulation. Conversely, GIP receptor activation may influence lipid metabolism and energy balance. Brzozowska P's research indicates that GIP promotes glucose uptake and lipid synthesis in adipocytes. However, under Retatrutid's influence, GIP signaling is modulated to optimize energy utilization rather than solely promoting fat storage, thereby aiding weight management\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cimg alt=\"\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/6a353479-4a12-4275-9cbe-51dfc761a962.png?v=1782900730\"\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFigure 1 Retatrutid’s mechanisms of action\u003c\/span\u003e\u003csup\u003e[3]\u003c\/sup\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eComprehensive Regulation of Metabolic Processes\u003c\/p\u003e\n\u003cp\u003eEnergy Metabolism Regulation: By activating the three receptors mentioned above, Retatrutid comprehensively regulates energy metabolism. It promotes lipolysis, increasing fatty acid entry into mitochondria for β-oxidation and enhancing energy expenditure. It reduces lipogenesis by inhibiting fatty acid uptake and triglyceride synthesis in adipocytes, thereby altering the body's energy storage and expenditure balance to facilitate weight loss. In relevant animal studies and clinical trials by Jastreboff A M, Retatrutid administration increased energy expenditure rates and progressively reduced body fat content in obese subjects\u003csup\u003e[4]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eGlucose Metabolism Regulation: Retatrutid modulates blood glucose through multiple pathways. Beyond stimulating insulin secretion via GLP-1 and GIP receptor activation, it influences hepatic glucose metabolism by regulating GCGR. It suppresses excessive hepatic gluconeogenesis, reduces glucose output, and simultaneously enhances peripheral tissue glucose uptake and utilization, thereby maintaining normal blood glucose levels. This is particularly crucial for obese patients with type 2 diabetes, effectively controlling blood glucose and improving diabetic conditions\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eLiver Metabolic Regulation: Within the liver, Retatrutid not only modulates glucose metabolism but also influences lipid metabolism. It reduces hepatic triglyceride synthesis and accumulation, improves hepatic steatosis, and holds potential therapeutic value for non-alcoholic fatty liver disease (NAFLD). In clinical trials involving participants with metabolic dysfunction-associated fatty liver disease (MDAFLD), Retatrutid significantly reduced hepatic fat content, demonstrating its positive regulatory effect on hepatic metabolism\u003csup\u003e[5]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e Effects on Gastrointestinal Function\u003c\/p\u003e\n\u003cp\u003eRetatrutid delays gastric emptying by activating GLP-1 receptors. Slower gastric emptying prolongs food residence time in the stomach, generating sustained satiety and reducing subsequent food intake. Simultaneously, it may influence gut hormone secretion and intestinal motility, further regulating gastrointestinal digestion and nutrient absorption processes, thereby comprehensively affecting energy intake and body weight\u003csup\u003e\u003cspan\u003e \u003c\/span\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eWhat is the synergistic mechanism between Retatrutid's agonistic effects on GLP-1, GCGR, and GIP receptors?\u003c\/p\u003e\n\u003cp\u003eSynergy in Energy Metabolism Regulation\u003c\/p\u003e\n\u003cp\u003eIncreased Energy Expenditure: Activation of GCGR promotes glycogenolysis and gluconeogenesis to elevate blood glucose levels. It also enhances energy expenditure by increasing lipid metabolism and suppressing food intake through central satiety. GLP-1R agonists stimulate insulin secretion and exert cardioprotective and neuroprotective effects, while also reducing energy intake by delaying gastric emptying and suppressing appetite. While GIPR activation in adipose tissue promotes lipid accumulation, its central activation reduces food intake and alleviates weight gain. Retatrutid simultaneously targets these three receptors, establishing a new equilibrium between energy intake and expenditure. This more effectively achieves an energy deficit, thereby facilitating weight loss.\u003c\/p\u003e\n\u003cp\u003eRegulating lipid metabolism: GCGR agonism enhances lipid metabolism, while GIPR activation in adipose tissue also influences lipid metabolism. GLP-1R agonists may indirectly affect lipid metabolism through mechanisms such as improving insulin sensitivity. Their synergistic action better regulates fat synthesis, breakdown, and transport, reducing fat accumulation and improving body fat distribution. For instance, studies in obese patients showed that after using Retatrutid for a period, body fat percentage decreased and lipid profiles improved to some extent, suggesting its synergistic effects in regulating fat metabolism\u003csup\u003e[6]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSynergistic Effects in Glucose Regulation\u003c\/p\u003e\n\u003cp\u003eEnhanced Insulin Secretion: GLP-1R agonists lower blood glucose by binding to GLP-1 receptors and promoting insulin secretion. GIP similarly stimulates pancreatic β-cells to produce insulin secretion effects similar to those induced by dietary intake. Retatrutid, which simultaneously activates GLP-1R and GIPR, significantly enhances insulin secretion, thereby more effectively lowering blood glucose levels. Although GCGR is typically associated with elevated blood glucose, its effects—such as promoting energy expenditure—can indirectly contribute to glucose stability when synergistically acting with receptors like GLP-1R. Furthermore, the combined use of GLP-1 and GCGR selectively counteracts the hyperglycemic risk induced by GCGR, enabling more precise and effective glucose regulation.\u003c\/p\u003e\n\u003cp\u003eRegulating Glucose Homeostasis: The synergistic activation of these three receptors extends beyond mere insulin secretion to encompass comprehensive glucose homeostasis regulation. By influencing glucose uptake, utilization, and storage across multiple tissues including liver, muscle, and adipose, Retatrutid maintains blood glucose within a relatively stable range, preventing significant fluctuations. In a study by Nicholls S involving type 2 diabetes patients, Retatrutid administration resulted in a significant reduction in glycated hemoglobin levels, indicating its positive impact on long-term glycemic control and demonstrating the synergistic effects of the three receptors in regulating glucose homeostasis\u003csup\u003e\u003cspan\u003e \u003c\/span\u003e[6]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSynergistic Activation of Signal Transduction Pathways\u003c\/p\u003e\n\u003cp\u003eCommon Signal Pathway Activation: GLP-1R, GCGR, and GIPR primarily signal through G (Gαs) proteins. When Retatrutid acts on these three receptors, it converges to activate shared downstream pathways such as the cAMP-PKA pathway. This shared pathway activation enhances signal transduction efficiency and potency, amplifying regulatory effects on cellular metabolism and physiological functions.\u003c\/p\u003e\n\u003cp\u003eCoordinating distinct pathways: While sharing common pathways, each receptor also activates unique signaling networks. Retatrutid modulates these distinct pathways synergistically during receptor activation, enabling coordinated metabolic regulation.\u003c\/p\u003e\n\u003cp\u003eSynergistic Regulation of Gastrointestinal Function\u003c\/p\u003e\n\u003cp\u003eInfluencing Gastrointestinal Hormone Secretion: GLP-1R agonists stimulate GLP-1 secretion, while GIPR agonists regulate GIP release. These gastrointestinal hormones play crucial roles in modulating gastrointestinal motility, digestion, and absorption. By simultaneously activating both receptors, Retatrutid provides more comprehensive regulation of gastrointestinal hormone secretion, thereby influencing gastrointestinal function. It may reduce rapid nutrient absorption by modulating gastric emptying rates and intestinal motility, aiding in weight and blood glucose control.\u003c\/p\u003e\n\u003cp\u003eImproving the Gastrointestinal Metabolic Environment: By regulating gastrointestinal hormone secretion, Retatrutid also enhances the metabolic environment within the gastrointestinal tract. It promotes the growth and metabolism of beneficial gut bacteria and modulates intestinal barrier function. These alterations may further influence the body's overall metabolic state. Working synergistically with effects on energy metabolism and blood glucose regulation, these mechanisms collectively contribute to the therapeutic effects against obesity and related metabolic disorders.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat are the applications of Retatrutid?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eObesity Treatment\u003c\/p\u003e\n\u003cp\u003eSignificant Weight Loss Effects: Multiple clinical trials demonstrate Retatrutid's efficacy in obesity treatment. In a Phase 2 double-blind, randomized, placebo-controlled trial by Jastreboff A M involving 338 adults, participants received weekly Retatrutid at varying doses or placebo for 48 weeks. Results showed that at week 24, the 1mg group achieved an average weight loss of 7.2%, the 4mg combination group lost 12.9%, the 8mg combination group lost 17.3%, and the 12mg group lost 17.5%, while the placebo group lost only 1.6%. By week 48, the 1mg group achieved an average weight loss of 8.7%, the 4mg combination group lost 17.1%, the 8mg combination group lost 22.8%, the 12mg group lost 24.2%, and the placebo group lost 2.1%. Among participants receiving 4mg, 8mg, and 12mg Retatrutid, 92%, 100%, and 100% achieved 5% or greater weight loss, respectively. 75%, 91%, and 93% achieved 10% or greater weight loss. and 60%, 75%, and 83% achieved 15% or greater weight loss, compared to 27%, 9%, and 2% in the placebo group. These data conclusively demonstrate Retatrutid's efficacy in weight reduction for obese patients\u003csup\u003e[4]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eType 2 Diabetes Treatment\u003c\/p\u003e\n\u003cp\u003eGlycemic Control Efficacy: Studies by Lopez D C et al. indicate Retatrutid positively impacts glycemic control in type 2 diabetes patients. In a trial involving 353 participants, Retatrutid reduced glycated hemoglobin (HbA1c) by 1.64% compared to placebo. This demonstrates Retatrutid's efficacy in lowering blood glucose levels in type 2 diabetes patients, thereby contributing to improved clinical outcomes\u003csup\u003e[7]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eCombined Mechanism Advantage: Retatrutid acts on multiple receptors, offering a unique advantage over single-receptor agonists through its combined agonist mechanism. It not only lowers blood glucose by stimulating insulin secretion but also enhances insulin sensitivity, enabling body cells to utilize insulin more effectively for comprehensive glycemic control. Its weight-reducing effects further improve metabolic status in type 2 diabetes patients, as obesity is a significant risk factor for the condition and weight loss facilitates better blood glucose management\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[5]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eTreatment of Non-Alcoholic Fatty Liver Disease\u003c\/p\u003e\n\u003cp\u003eReducing Liver Fat Content: Retatrutid demonstrated the ability to reduce liver fat content in patients with metabolic dysfunction-associated fatty liver disease (MDAFLD) and liver fat content ≥10%. In a randomized, double-blind, placebo-controlled trial, 98 participants were randomly assigned to receive weekly subcutaneous injections of Retatrutid (1mg, 4mg, 8mg, or 12mg) or placebo for 48 weeks. Results showed that at week 24, the mean change in hepatic fat content relative to baseline was -42.9% in the 1mg group, -57.0% in the 4mg group, -81.4% in the 8mg group, and -82.4% in the 12mg group, compared to +0.3% in the placebo group. These findings indicate that Retatrutid significantly reduces hepatic fat content, demonstrating potential therapeutic value for non-alcoholic fatty liver disease\u003csup\u003e[8]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eImproving Hepatic Metabolic Function: Retatrutid enhances liver metabolic function by regulating energy and lipid metabolism. It promotes the oxidation and breakdown of hepatic fats, reduces fat accumulation in the liver, modulates inflammatory responses and oxidative stress levels within the liver, and exerts a certain inhibitory effect on the progression of NAFLD, thereby protecting patients' liver health.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs a triple receptor agonist of GLP-1R\/GIPR\/GCGR, Retatrutid exerts metabolic regulatory effects through a multi-target synergistic mechanism. Its effects encompass activating GLP-1R to suppress appetite and delay gastric emptying, thereby reducing energy intake; activating GIPR to enhance insulin secretion and improve insulin sensitivity; and activating GCGR to promote lipolysis and energy expenditure while regulating hepatic glucose and lipid metabolism to reduce fat accumulation. This triple synergy achieves comprehensive effects including potent glycemic control, significant weight loss, and improved lipid and hepatic fat metabolism. Its core value lies in obesity treatment, achieving dose-dependent weight reduction with a maximum 48-week loss of 24.2%. For type 2 diabetes, it effectively lowers glycated hemoglobin and improves glycemic homeostasis. In metabolic dysfunction-associated fatty liver disease, it significantly reduces hepatic fat content, demonstrating potent efficacy across multiple metabolic disorders.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAbout The Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe above-mentioned materials are all researched, edited and compiled by Cocer Peptides.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eScientific Journal Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eArun J. Sanyal is a hepatologist and researcher specializing in liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). He is affiliated with the Virginia Commonwealth University School of Medicine, where he has been a faculty member since 1989. Sanyal has authored approximately 1,000 publications in leading journals such as Cell Metabolism, Nature Medicine, The New England Journal of Medicine, and The Lancet. His work has been cited over 104,000 times, reflecting his significant impact on the field of hepatology. He has been continuously funded by the National Institutes of Health since 1995 and is the principal investigator of four active NIH grants. Sanyal has also been recognized for his leadership in clinical research and his contributions to the development of therapeutic strategies for liver diseases. Arun J. Sanyal is listed in the reference of citation [5].\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRelevant Citations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e[1] Brzozowska P, Frańczuk A, Nowińska B, Makłowicz A, Palacz KA, Lenartowicz I. Retatrutid - revolutionary recently developed GLP agonist - literature review. Quality in Sport 2024.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/api.semanticscholar.org\/CorpusID:271031379\"\u003ehttps:\/\/api.semanticscholar.org\/CorpusID:271031379\u003c\/a\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[2] Doggrell SA. Retatrutid showing promise in obesity (and type 2 diabetes).\u003cspan\u003e \u003c\/span\u003e\u003cem\u003eExpert Opinion On Investigational Drugs\u003c\/em\u003e\u003cspan\u003e \u003c\/span\u003e2023;\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e32\u003c\/strong\u003e(11): 997-1001.DOI: 10.1080\/13543784.2023.2283020.\u003c\/p\u003e\n\u003cp\u003e[3] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutid—A Game Changer in Obesity Pharmacotherapy. Biomolecules 2025; 15(6).DOI: 10.3390\/biom15060796.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[4] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutid for Obesity - A Phase 2 Trial.\u003cspan\u003e \u003c\/span\u003e\u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e\u003cspan\u003e \u003c\/span\u003e2023;\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e389\u003c\/strong\u003e(6): 514-526. DOI:10.1056\/NEJMoa2301972.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[5] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.\u003cspan\u003e \u003c\/span\u003e\u003cem\u003eNature Medicine\u003c\/em\u003e\u003cspan\u003e \u003c\/span\u003e2024;\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e30\u003c\/strong\u003e: 2037-2048. https:\/\/api.semanticscholar.org\/CorpusID:270378167.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[6] Nicholls S, Pirro V, Lin Y, et al. Triple-hormone receptor agonist retatrutide significantly improves lipoprotein and apolipoprotein profiles in participants with obesity or overweight.\u003cspan\u003e \u003c\/span\u003e\u003cem\u003eEuropean Heart Journal\u003c\/em\u003e\u003cspan\u003e \u003c\/span\u003e2024;\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e45\u003c\/strong\u003e(Supplement_1): ehae666-ehae1501.DOI:10.1093\/eurheartj\/ehae666.1501.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[7] Lopez DC, Pajimna JT, Milan MD, et al. 7792 Efficacy of Retatrutid for Weight Reduction and Its Cardiometabolic Effects Among Adults: A Systematic Review and Meta-Analysis.\u003cspan\u003e \u003c\/span\u003e\u003cem\u003eJournal of the Endocrine Society\u003c\/em\u003e\u003cspan\u003e \u003c\/span\u003e2024;\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e8\u003c\/strong\u003e(Supplement_1): bvae163-bvae749.DOI: 10.1210\/jendso\/bvae163.749.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[8] Naeem M, Imran L, Banatwala U. Unleashing the power of retatrutide: A possible triumph over obesity and  overweight: A correspondence. Health Science Reports 2024; 7(2): e1864.DOI: 10.1002\/hsr2.1864.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  \u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv id=\"location_1750667616587\" data-type=\"locations\" data-level=\"rows\"\u003e\n\u003cdiv class=\"backstage-stwidgets-settingwrap\" scope=\"0\" id=\"component_yPKEnHFkjZhO\"\u003e\n\u003cdiv class=\"sitewidget-gallery sitewidget-proddetail sitewidget-162f6be7-60af-409f-a195-fbc2d9ed0d20-20250624132610 prod_des_sitewidget-162f6be7-60af-409f-a195-fbc2d9ed0d20-20250624132610\"\u003e\n\u003cdiv class=\"sitewidget-bd\"\u003e\n\u003cdiv class=\"detial-cont-divsions detial-cont-prodescription detial-cont-prodescription_pc prod_floating_mt\"\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_3\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003eThe products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_4\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267677937888,"sku":null,"price":480.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/1d345569-0894-41a5-b99a-487ff0caf410.png?v=1782900873"},{"product_id":"glow-70mg-blend","title":"Glow 70mg （Blend）","description":"\u003cp\u003e\u003cspan\u003eTB4, a synthetic analog of Thymosin Beta-4, exhibits multiple biological activities by regulating actin dynamics in the cytoskeleton, promoting cell migration, proliferation, and differentiation, and playing a key role in tissue repair and regeneration.\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eBPC 157, a synthetic peptide, demonstrates extensive biological functions, including tissue repair, neuroprotection, anti-ulcer, anti-inflammatory, and antioxidant effects, with notable efficacy in accelerating wound healing and supporting gastrointestinal and liver health.\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eGHK-Cu, a tripeptide copper chelate, displays a broad spectrum of biological activities such as antioxidant, anti-inflammatory, and collagen-synthesis promotion, offering significant benefits for skin health and tissue repair.\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eThe combination of TB500, BPC157, and GHK-Cu presents synergistic advantages in wound healing, tissue repair, anti-inflammation, neuroprotection, and skin health and beauty.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003cspan\u003eTB4\u003c\/span\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003eAs a synthetic analog of Thymosin Beta-4 (Tβ4), TB4 is a polypeptide molecule with multiple biological activities. Its core mechanism of action is achieved by precisely regulating the dynamic balance between the polymerization and depolymerization of actin in the cytoskeleton. This molecule can significantly promote cell migration, proliferation, and differentiation, thereby playing a key regulatory role in the process of tissue repair and regeneration. In the repair of skin wounds, TB4 can accelerate wound closure, promote the orderly deposition of collagen, and inhibit the abnormal proliferation of pathological scar tissue. In the field of metabolic diseases, it alleviates inflammation-related pathological processes such as non-alcoholic fatty liver disease and pulmonary fibrosis by inhibiting the release of pro-inflammatory factors. In terms of cardiovascular protection, during the acute phase of myocardial infarction, TB4 can effectively protect surviving cardiomyocytes, activate the endogenous angiogenesis mechanism, optimize the myocardial microcirculation, and ultimately improve the cardiac pumping function. It is worth noting that TB4 exhibits high bioavailability, synergistic effects at multiple targets, and excellent biocompatibility. Its unique tissue-targeting property enables it to directly act on the microenvironment of damaged tissues. While achieving precise treatment, it significantly reduces the risk of systemic exposure, providing a theoretical basis and practical support for clinical applications.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv id=\"location_1750667616587\" data-type=\"locations\" data-level=\"rows\"\u003e\n\u003cdiv class=\"backstage-stwidgets-settingwrap\" scope=\"0\" id=\"component_yPKEnHFkjZhO\"\u003e\n\u003cdiv class=\"sitewidget-gallery sitewidget-proddetail sitewidget-162f6be7-60af-409f-a195-fbc2d9ed0d20-20250624132610 prod_des_sitewidget-162f6be7-60af-409f-a195-fbc2d9ed0d20-20250624132610\"\u003e\n\u003cdiv class=\"sitewidget-bd\"\u003e\n\u003cdiv class=\"detial-cont-divsions detial-cont-prodescription detial-cont-prodescription_pc prod_floating_mt\"\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_1\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003eBpc157\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eBPC 157 is a synthetic peptide composed of fifteen amino acids, and its full name is Body Protection Compound 157. This molecule was initially obtained by isolating proteins from gastric juice and then artificially synthesizing them. Research shows that BPC 157 has a wide range of biological functions, including promoting tissue repair, neuroprotection, anti-ulcer, anti-inflammatory, and antioxidant effects. In the field of tissue repair, BPC 157 can significantly accelerate the healing process of connective tissues such as the skin, tendons, and ligaments, especially showing excellent efficacy in the repair of burn wounds. Its mechanism of action involves enhancing the proliferation, migration, and tubule formation abilities of endothelial cells, thereby promoting angiogenesis and tissue regeneration. In terms of neuroprotection, BPC 157 plays a positive role in the central nervous system by regulating the levels of neurotransmitters such as serotonin and dopamine, and can improve problems such as indigestion, malabsorption, and immunodeficiency.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn addition, BPC 157 exhibits significant anti-ulcer and anti-inflammatory properties, which can maintain the integrity of the gastrointestinal mucosa and prevent the invasion of pathogens and toxins into the intestine. In terms of liver protection, this molecule has a significant protective effect on liver function by inhibiting abnormal cell proliferation, maintaining the structural integrity of hepatocytes, stabilizing enzymatic indices, reducing the levels of inflammatory factors, and inhibiting the process of liver fibrosis. Compared with other drugs, the advantage of BPC 157 lies in its low toxicity and the absence of significant side effects, showing good safety and tolerability in various animal models. Currently, BPC 157 not only has unique therapeutic effects in the treatment of gastrointestinal diseases but also shows potential application values in promoting tissue regeneration, improving the function of the central nervous system, and the field of anti-aging.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_2\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e \u003cspan\u003e\u003cstrong\u003e▎\u003c\/strong\u003e\u003c\/span\u003e\u003cspan\u003e\u003cstrong\u003eBpc157\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eAs a naturally derived tripeptide copper chelate, GHK-Cu is a multifunctional bioactive molecule. Its core structure is a stable complex formed by the tripeptide of glycine-histidine-lysine and copper ions. By regulating the dynamic metabolic process of copper ions, this molecule exhibits a wide range of biological activities, including antioxidant, anti-inflammatory, and promoting collagen synthesis. In the field of beauty and skin care, GHK-Cu can effectively alleviate skin aging, accelerate the wound healing process, enhance skin elasticity, and at the same time exert significant anti-inflammatory and antioxidant effects. In addition, its biological activities are also reflected in promoting hair health, regulating gene expression, and assisting in the treatment of specific diseases. As an emerging bioactive molecule, GHK-Cu shows great application potential in delaying aging, improving the skin microenvironment, and enhancing tissue repair ability. Its multi-target mechanism of action endows it with broad application prospects in the fields of beauty, anti-aging, and medical care. Current research further shows that GHK-Cu may realize its cross-disciplinary application value in biomedicine and cosmetic science through multiple mechanisms such as regulating cell signaling pathways, enhancing cell metabolic activity, and optimizing the tissue microenvironment.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_3\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cspan\u003e\u003cstrong\u003e▎\u003c\/strong\u003e\u003c\/span\u003e\u003cspan\u003e\u003cstrong\u003eSummary\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eThe combined use of TB500, BPC157, and GHK-Cu has many potential effects and benefits in wound healing, tissue repair, anti-inflammation, neuroprotection, and skin health and beauty.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e1. Skin Health and Beauty\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImproving skin elasticity: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGHK-Cu can promote the production of collagen and elastin, making the skin firmer and more elastic. Collagen and elastin are important components for maintaining skin elasticity. The effect of GHK-Cu can increase skin elasticity and reduce the appearance of wrinkles and fine lines. TB500 and BPC157 can promote the repair and regeneration of skin cells. They can accelerate the healing of skin wounds, reduce scar formation, and at the same time promote the metabolism of skin cells, making the skin healthier.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eThe combined use of these three substances may have significant effects in anti-aging and beauty skin care. They act on the skin together, improving the health and appearance of the skin from different aspects, making the skin younger and more vibrant.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePromoting skin repair: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor skin injuries such as burns, scalds, and cuts, these three substances can accelerate the skin healing process and reduce scar formation. BPC157 has shown a significant effect in promoting skin wound healing in a rat model of alkali burns. It can accelerate wound closure and promote granulation tissue formation, re-epithelialization, dermal remodeling, and collagen deposition\u003csup\u003e[1]\u003c\/sup\u003e. TB500 and GHK-Cu may also accelerate the skin healing process by promoting cell growth and repair, as well as the production of collagen.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e2. Wound Healing and Tissue Repair\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAccelerating wound healing: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBoth TB500 and BPC157 have the effect of promoting wound healing. TB500 can accelerate cell migration and proliferation, promote angiogenesis, and accelerate collagen synthesis and tissue repair. BPC157 also performs well in this regard. It can induce the production of nitric oxide and promote the migration of vascular endothelial cells, thus accelerating wound healing.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eGHK-Cu helps the skin restore its self-repair ability by promoting the production of collagen and elastin. Collagen and elastin are important components of skin tissue, and their production is helpful for wound healing and tissue repair.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eWhen these three substances are used in combination, their synergistic effect may further accelerate the wound healing speed and shorten the healing time. The three substances promote wound healing from different perspectives. TB500 and BPC157 mainly promote cell migration, proliferation, and angiogenesis, while GHK-Cu promotes the production of collagen and elastin. Under the combined action, the wound may heal faster.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImproving the quality of tissue repair: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTB500 contributes to the orderly repair of tissues. It may regulate cell growth and differentiation and promote the normal repair process of tissues, making the repaired tissues more orderly. BPC157 can enhance the integrity and stability of tissues. For example, in the study of tendon healing, BPC157 promoted the growth of tendon fibroblasts from tendon explants, increased cell survival under stress conditions, and promoted cell migration, which may help enhance the integrity and stability of tissues\u003csup\u003e[2]\u003c\/sup\u003e. GHK-Cu can promote the regeneration of skin stem cells. Skin stem cells play a key role in tissue repair. They can differentiate into various skin cells, making the repaired tissues healthier and more elastic.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e3. Anti-inflammatory Effect\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReducing the inflammatory response: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBoth BPC157 and TB500 have anti-inflammatory properties. As an antioxidant, GHK-Cu can also neutralize the free radicals generated during the inflammatory process, further reducing inflammation. Free radicals can damage tissues during the inflammatory process, and the antioxidant effect of GHK-Cu can reduce the generation of free radicals, thus alleviating the inflammatory response.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eThe combined use of these three substances may have better therapeutic effects in treating inflammatory diseases such as arthritis and muscle inflammation. They exert anti-inflammatory effects from different mechanisms, and when used in combination, they may produce a synergistic effect and more effectively reduce the inflammatory response.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e4. Neuroprotection and Nerve Repair\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePromoting nerve repair: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBPC157 has a protective effect on the nervous system, which can promote the growth and repair of nerve cells and improve nerve function. For example, some studies have shown that the protective effect of BPC157 on the nervous system may be related to its activation of the Src-Cav-1-eNOS pathway\u003csup\u003e[3]\u003c\/sup\u003e. GHK-Cu provides a favorable growth environment for nerve cells by promoting the production of collagen. Collagen also plays an important role in nerve tissue. It can provide support and nutrients for nerve cells and promote the growth and repair of nerve cells.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eThe synergistic effect of these three substances may help treat nerve injuries and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. The three substances promote nerve repair from different angles. BPC157 and TB500 directly act on nerve cells to promote their growth and repair, while GHK-Cu indirectly plays a role by improving the growth environment of nerve cells.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAbout The Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe above-mentioned materials are all researched, edited and compiled by Cocer Peptides.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_4\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e▎\u003c\/span\u003eRelevant Citations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[1] Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and  promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther 2015; 9: 2485-99.DOI:10.2147\/DDDT.S82030.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[2] Chang C, Tsai W, Lin M, Hsu Y, Pang JS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves  tendon outgrowth, cell survival, and cell migration. J APPL PHYSIOL 2011; 110(3): 774-80.DOI:10.1152\/japplphysiol.00945.2010.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[3] Hsieh M, Lee C, Chueh H, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of  Src-Caveolin-1-endothelial nitric oxide synthase pathway.\u003cspan\u003e \u003c\/span\u003e\u003cem\u003eSCI REP-UK\u003c\/em\u003e\u003cspan\u003e \u003c\/span\u003e2020;\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e10\u003c\/strong\u003e(1): 17078.DOI:10.1038\/s41598-020-74022-y.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"row\" data-type=\"rows\" data-level=\"rows\"\u003e\n\u003cdiv class=\"col-md-12 col-md-first col-md-last\" id=\"column_1750741485987\" data-type=\"columns\" data-level=\"columns\"\u003e\n\u003cdiv id=\"location_1750741485989\" data-type=\"locations\" data-level=\"rows\"\u003e\n\u003cdiv class=\"backstage-stwidgets-settingwrap\" id=\"component_zofEdwDNPUbt\" data-scope=\"0\" data-settingid=\"zofEdwDNPUbt\" data-relationcommonid=\"dUKAZpoOYViE\" data-classattr=\"sitewidget-placeHolder-20250623183551\"\u003e\n\u003cdiv class=\"sitewidget-placeholder sitewidget-placeHolder-20250623183551\"\u003e\n\u003cdiv class=\"sitewidget-bd\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267684229344,"sku":null,"price":260.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/44e63d46-6de2-44a3-861f-d83f6fc6ef71.png?v=1782901044"},{"product_id":"na-sema-50mg","title":"NA Sema 50mg","description":"\u003cp\u003e\u003cspan\u003eNA Sema 50 mg offers a higher dosage option for research, enabling in-depth exploration of its neuromodulatory effects. It participates in central signaling regulation by influencing neurotransmitter release and neuroplasticity processes. This dosage specification facilitates the study of dose-related effects and neuromodulatory mechanisms, providing valuable reference for cognitive and neurological function research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267688849632,"sku":null,"price":320.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/75406514-15ae-451b-a8c3-c97c6eb496e0.png?v=1782901334"},{"product_id":"na-sema-10mg","title":"NA Sema 10mg","description":"\u003cp\u003e\u003cspan\u003eNA Sema is the deamidated form of Sema, primarily acting on the central nervous system. It participates in pathways related to neurotransmitter regulation, neuroplasticity, and stress responses. Its mechanism involves neurotrophic signaling and synaptic regulation, making it significant for research into cognitive function and neuromodulatory processes. It holds considerable importance in neuroscience and behavioral regulation studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267689930976,"sku":null,"price":60.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/7cb2c91a-54d7-4766-b6a4-51cc4f5297b6.png?v=1782901412"},{"product_id":"tesamoreli-ipamorelin-cjc1295-6-3-3blend","title":"Tesamoreli,Ipamorelin,CJC1295 6\/3\/3(Blend)","description":"\u003cp\u003e\u003cspan\u003eThis triple combination is used to study the multi-level synergistic regulatory mechanisms of the growth hormone axis. Tesamoreli primarily acts on upstream regulatory signals, Ipamorelin stimulates growth hormone release through selective pathways, while CJC-1295 prolongs the duration of endogenous signaling. By covering distinct regulatory nodes, this triad enables systematic investigation of GH secretion rhythms, feedback control, and endocrine system synergism. This combination holds significant model research value for studies on the growth axis, circadian rhythms, and metabolism.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267691634912,"sku":null,"price":200.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/4f956227-8466-4ebb-9f19-8ca7020d6175.png?v=1782901509"},{"product_id":"kpv-30mg","title":"KPV 30mg","description":"\u003cp\u003e\u003cspan\u003eKPV is a functional tripeptide fragment of α-MSH (melanocyte-stimulating hormone) that has garnered significant attention in immunological and inflammatory regulation research. Its primary functions involve modulating inflammation-related signaling and maintaining immune homeostasis. KPV influences multiple inflammatory factor pathways, regulating the intensity of immune responses at the cellular level. Its mechanisms involve interacting with receptors and downstream pathways associated with immune cell signaling, thereby affecting intercellular communication and response balance. KPV holds significant research value in studies of inflammatory mechanisms, immune regulation, and gut-barrier function.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003cspan\u003eWhat is KPV?\u003c\/span\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003eKPV is a natural peptide segment with multiple biological activities. It performs remarkably well in the field of anti-inflammation. By regulating the immune response, it alleviates inflammation, which is of great significance for the treatment of diseases such as inflammatory bowel disease. Meanwhile, KPV has antibacterial effects against pathogens such as Staphylococcus aureus and Candida albicans, helping to reduce infections. In addition, it can accelerate wound healing, promote tissue repair, and improve skin health in the field of cosmetology. KPV has excellent water solubility and biocompatibility. It will not trigger an immune response, and can be naturally degraded by the action of enzymes in the body, ensuring a high level of safety. Its multifunctionality endows it with broad application prospects in multiple fields, including medicine, cosmetology, and biomaterials.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003cspan\u003eTKPV Structure\u003c\/span\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/1270a90d-891b-449f-a134-890db785da7a.png?v=1782901861\" alt=\"\"\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cp\u003eIUPAC Condensed：H-Lys-Pro-Val-OH\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C\u003csub\u003e16\u003c\/sub\u003eH\u003csub\u003e30\u003c\/sub\u003eN\u003csub\u003e4\u003c\/sub\u003eO\u003csub\u003e4\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp\u003eMolecular Weight: 342.43g\/mol\u003c\/p\u003e\n\u003cp\u003eCAS Number: 67727-97-3\u003c\/p\u003e\n\u003cp\u003ePubChem CID: 125672\u003c\/p\u003e\n\u003cp\u003eSynonyms: Msh (11-13)；alpha-Msh (11-13)；ACTH-(11-13)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKPV Research\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the research background of KPV?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKPV is a tripeptide derived from α-melanocyte-stimulating hormone (α-MSH). α-MSH is a polypeptide hormone with multiple biological functions, playing an important role in regulating skin pigmentation, immune regulation, and other aspects. As a part of α-MSH, KPV has been isolated and deeply studied. Although some progress has been made in the medical field in recent years, the treatment options for inflammatory bowel disease (IBD) are still unsatisfactory, and the surgery rate remains high. Therefore, finding new and effective treatment methods has become an urgent task. IBD includes ulcerative colitis, Crohn's disease, etc., which are characterized by chronic intestinal inflammation and seriously affect the quality of life of patients. Current treatment methods include drug therapy and surgical treatment, but both have certain limitations. In recent years, the anti-inflammatory effects of melanocortin peptides such as α-MSH have been described in dextran sulfate sodium (DSS) colitis in mice. This provides a clue for studying the anti-inflammatory potential of KPV. α-MSH has functions such as immune regulation and inflammation alleviation, and the tripeptide KPV derived from it is also considered to possibly have similar anti-inflammatory properties.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the mechanism of action of KPV?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of action in ulcerative colitis\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImproving stability and rectal administration convenience:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eKPV (Lys-Pro-Val) is a tripeptide derived from α-MSH (α-melanocyte-stimulating hormone) and has anti-inflammatory effects against colitis. However, the KPV solution is very unstable during rectal administration, affecting its therapeutic effect. In the study, cysteamine-grafted γ-polyglutamic acid (SH-PGA) was synthesized by combining cysteamine with the carboxyl group of γ-PGA. Without using a cross-linking agent, a 4% polymer content SH-PGA hydrogel was formed through the self-cross-linking of sulfhydryl groups. The KPV\/SH-PGA hydrogel showed an elastic modulus (G') higher than the corresponding viscous modulus (G'') at 0.01-10 Hz, exhibiting good mechanical stability and shear thinning behavior, which is beneficial for rectal administration. At the same time, the stability of KPV in the SH-PGA hydrogel was significantly enhanced. Only 30% of KPV was released from the KPV\/SH-PGA hydrogel within 20 minutes, followed by a continuous release behavior\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAlleviating colitis symptoms:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eThrough experiments on rats with ulcerative colitis induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS), the enhanced therapeutic effect of the KPV\/SH-PGA hydrogel on colitis was confirmed. After rectal administration of the KPV\/SH-PGA hydrogel, colitis symptoms including weight loss and disease activity index scores were significantly alleviated. In addition, treatment with the KPV\/SH-PGA hydrogel prevented the shortening of the colon in rats injected with TNBS and reduced the level of colonic myeloperoxidase. After treatment with the KPV\/SH-PGA hydrogel, the morphology of the colon, including the epithelial barrier, crypts, and intact goblet cells, was restored. At the same time, the KPV\/SH-PGA hydrogel reduced the expression of pro-inflammatory cytokines such as tumor necrosis factor α and interleukin 6\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of action in mouse models of inflammatory bowel disease\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDSS colitis model: In the DSS colitis model, treatment with KPV led to earlier recovery and significantly enhanced weight recovery. Histologically, the inflammatory infiltration in KPV-treated mice was significantly reduced, which was confirmed by the significant decrease in the activity of myeloperoxidase (MPO) in the colonic tissue after KPV treatment\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCD45RB (hi) transfer colitis model:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eSupporting the above findings, KPV treatment of transferred colitis led to disease recovery, weight recovery, and a reduction in inflammatory changes from a histological perspective\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMC1Re\/e mouse model:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eIn mice expressing a non-functional melanocortin-1 receptor (MC1Re\/e), KPV treatment saved all animals in the treatment group from death during DSS colitis. This indicates that the anti-inflammatory effect of KPV seems to be at least partially independent of MC1R signaling\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of action in bronchial epithelial cell inflammation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eI\u003cstrong\u003enhibiting NF-κB signaling:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eIn immortalized human bronchial epithelial cells, the melanocortin-related peptide KPV and the agonist α-MSH of airway epithelium (MC3R) inhibited NF-κB signaling by inhibiting the nuclear import of p65RelA and activating epithelial MC3R, respectively. Specifically, the effect of KPV is related to its nuclear import, which can inhibit the nuclear translocation of p65RelA labeled with YFP. At the same time, the binding sites of KPV and Imp-α\/β are on p65RelA, possibly involving blocking importin-α armadillo domains 7 and 8\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[3]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of action in chemotherapy-induced oral mucositis\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAntibacterial, anti-inflammatory, and repair effects:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eUsing temperature-sensitive PLGA-PEG-PLGA (PPP) as the matrix and epigallocatechin-3-gallate (EGCG) with inherent antibacterial activity as the adhesion enhancer, an in-situ mucosal adhesive hydrogel (PPP_E) was successfully prepared. The tripeptide KPV was dissolved in the cold PPP_2% E precursor solution as a model drug to prepare the KPV@PPP_2% E hydrogel. The anti-inflammatory activity and the potential to promote cell migration of KPV in the PPP-2% E hydrogel were well maintained. In addition, the KPV@PPP_2% E had a strong antibacterial effect against Staphylococcus aureus. When the KPV@PPP_2% E hydrogel was applied to the gingival mucosa of rats with chemotherapy-induced oral mucositis, it could rapidly transform into a hydrogel and adhere to the wound surface for 7 hours, greatly improving the food intake and weight recovery of the rats. At the same time, by promoting the expression of CK10 and PCNA, the KPV@PPP_E hydrogel also well repaired the tissue morphology of the ulcerated gingiva. In addition, the KPV@PPP_2% E hydrogel significantly inhibited inflammatory cytokines including IL-1β and TNF-α, and at the same time upregulated IL-10\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[4]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/1f57c3df-25e9-4403-977c-cd3b89d8cc71.png?v=1782901914\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cdiv id=\"location_1750667616587\" data-type=\"locations\" data-level=\"rows\"\u003e\n\u003cdiv class=\"backstage-stwidgets-settingwrap\" scope=\"0\" id=\"component_yPKEnHFkjZhO\"\u003e\n\u003cdiv class=\"sitewidget-gallery sitewidget-proddetail sitewidget-162f6be7-60af-409f-a195-fbc2d9ed0d20-20250624132610 prod_des_sitewidget-162f6be7-60af-409f-a195-fbc2d9ed0d20-20250624132610\"\u003e\n\u003cdiv class=\"sitewidget-bd\"\u003e\n\u003cdiv class=\"detial-cont-divsions detial-cont-prodescription detial-cont-prodescription_pc prod_floating_mt\"\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_2\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003eSource:PubMed\u003csup\u003e[5]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat are the clinical application cases of KPV drugs?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTreatment of ulcerative colitis\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdministration through self-crosslinking hydrogel: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn a study, cysteamine-grafted γ-polyglutamic acid (SH-PGA) was synthesized and made into a hydrogel to stabilize the tripeptide KPV\u003csup\u003e[1]\u003c\/sup\u003e. The KPV\/SH-PGA hydrogel showed good therapeutic effects in a rat model of ulcerative colitis induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS). Specifically, after rectal administration, colitis symptoms such as weight loss and disease activity index scores were significantly alleviated, and it could also prevent the shortening of the colon in rats injected with TNBS and reduce the level of colonic myeloperoxidase. At the same time, the morphology of the colon, including the epithelial barrier, crypts, and intact goblet cells, was restored after treatment with the KPV\/SH-PGA hydrogel, and the hydrogel also reduced the expression of pro-inflammatory cytokines such as tumor necrosis factor α and interleukin 6.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdministration through dual-network hydrogel:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eAnother study constructed a dual-network hydrogel (PMSP) formed by maleated γ-polyglutamic acid and thiolated γ-polyglutamic acid through thiol-maleimide cross-linking and self-oxidation of thiols\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[5]\u003c\/sup\u003e. This hydrogel can specifically adhere to the inflamed mucosa rather than the healthy mucosa, and has good mechanical strength and biological adhesion. KPV, as a model drug, is easily captured by PMSP through electrostatic interaction, thus maintaining its biological activity for a longer time under high-temperature conditions. In rats with colitis induced by TNBS, after rectal administration of PMSP-KPV, the alleviating effect of KPV on colitis was significantly improved, and the epithelial barrier of the colon was effectively restored. In addition, PMSP-KPV also regulated the intestinal flora and significantly increased the abundance of beneficial microorganisms in the intestine.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor chemotherapy-induced oral mucositis\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAn in-situ mucosal adhesive hydrogel (PPP_E) was prepared using temperature-sensitive PLGA-PEG-PLGA (PPP) as the matrix and epigallocatechin-3-gallate (EGCG) as the adhesion enhancer\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[4]\u003c\/sup\u003e. The tripeptide KPV was dissolved in the cold PPP_2% E precursor solution as a model drug to prepare the KPV@PPP_2% E hydrogel. This hydrogel has anti-inflammatory, antibacterial, and repair effects on chemotherapy-induced oral mucositis. Specifically, it can maintain the anti-inflammatory activity of KPV and the potential to promote cell migration, and has a strong antibacterial effect against Staphylococcus aureus. After administration to the gingival mucosa of rats with chemotherapy-induced oral mucositis, the PPP_2% E precursor solution rapidly transformed into a hydrogel and adhered to the wound surface for 7 hours. Treatment with the KPV@PPP_2% E hydrogel greatly improved the food intake and weight recovery of the rats, promoted the expression of CK10 and PCNA, well repaired the tissue morphology of the ulcerated gingiva, and at the same time significantly inhibited inflammatory cytokines such as IL-1β and TNF-α, and upregulated the expression of IL-10. This hydrogel also has an antibacterial effect on gingival ulcer wounds infected with methicillin-resistant Staphylococcus aureus (MRSA), and significantly inhibits the infiltration of inflammatory cells into the submucosal tissue.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTreatment of inflammatory bowel disease\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSome studies have shown that KPV may be a new therapeutic drug for inflammatory bowel disease (IBD)\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[6]\u003c\/sup\u003e. In human intestinal epithelial cells (Caco2-BBE and HT29-Cl.19A) and human T cells (Jurkat), after stimulation with pro-inflammatory cytokines, the addition of KPV can inhibit the activation of NF-κB and MAP kinase inflammatory signaling pathways and reduce the secretion of pro-inflammatory cytokines. The study found that KPV acts through hPepT1 expressed in immune and intestinal epithelial cells. In addition, in mouse models of colitis induced by dextran sulfate sodium (DSS) and TNBS, oral administration of KPV can reduce the expression of pro-inflammatory cytokines and the incidence of colitis.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn conclusion, as a bioactive substance with great potential, KPV shows unique advantages in the treatment of various diseases. In the field of inflammatory bowel disease, whether in mouse model experiments or in the exploration of different administration methods for ulcerative colitis, KPV can effectively reduce inflammatory infiltration, improve tissue morphology, regulate cytokine expression, and exert significant anti-inflammatory effects through mechanisms such as PepT1 transport. In the treatment of chemotherapy-induced oral mucositis, the hydrogel containing KPV prepared with a specific matrix and adhesion enhancer can not only maintain its anti-inflammatory and cell migration-promoting activities but also has a powerful antibacterial ability, significantly improving the related symptoms of rats and promoting tissue repair. Although the current clinical application cases of KPV are still limited, the existing research results fully demonstrate its therapeutic value. In the future, if breakthroughs can be achieved in in-depth research on improving drug stability and delivery efficiency, expanding clinical indications, and strengthening clinical monitoring and management, KPV is expected to bring more high-quality and efficient treatment options for more patients and play a more important role in clinical treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAbout The Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe above-mentioned materials are all researched, edited and compiled by Cocer Peptides.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eScientific Journal Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDalmasso G is a researcher in the field of medicine, with research directions covering medicine, biochemistry, and genetics, among other areas. He has worked at several prestigious institutions, including Universite Clermont Auvergne (UCA), CHU Clermont Ferrand, INRAE, Institut National de la Sante et de la Recherche Medicale (Inserm), Clermont Univ, Georgia State University, Emory University, Universite Cote d'Azur, and Universidad Nacional Rio Cuarto. These institutions are highly reputed in their respective fields, and Dalmasso G's collaborations with them have contributed to the advancement of related disciplines. His research findings may be of great significance to the development of medical science, particularly in improving disease treatment outcomes and patients' quality of life. Dalmasso G is listed in the reference of citation [6].\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_3\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e▎\u003c\/span\u003eRelevant Citations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[1] Sun J, Xue P, Liu J, et al. Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats[J]. Acs Biomaterials Science \u0026amp; Engineering, 2021,7(10):4859-4869.DOI:10.1021\/acsbiomaterials.1c00792.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[2] Konnengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease[J]. Inflammatory Bowel Diseases, 2008,14(3):324-331.DOI:10.1002\/ibd.20334.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[3] Land S C. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.[J]. International Journal of Physiology, Pathophysiology and Pharmacology, 2012,4(2):59-73. https:\/\/pubmed.ncbi.nlm.nih.gov\/22837805\/\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[4] Shao W, Chen R, Lin G, et al. In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis[J]. Biomaterials Science, 2021,10(1):227-242.DOI:10.1039\/d1bm01466h.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[5] Zhao Y, Xue P, Lin G, et al. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon[J]. Acta Biomaterialia, 2022,143:233-252.DOI:10.1016\/j.actbio.2022.02.039.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[6] Dalmasso G, Charrier-Hisamuddin L, Nguyen H T T, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation[J]. Gastroenterology, 2008,134(1):166-178.DOI:10.1053\/j.gastro.2007.10.026.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_4\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267700383968,"sku":null,"price":220.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/a0227ad6-e48f-4eec-87a1-7641fc355cbf.png?v=1782901938"},{"product_id":"tesamoreli-ipamorelin-10-3blend","title":"Tesamoreli,Ipamorelin 10\/3(Blend)","description":"\u003cp\u003e\u003cspan\u003eTesa Ipa Blend combines Tesamoreli with Ipamorelin to investigate the multi-pathway regulation of growth hormone release. Tesamoreli primarily acts on upstream regulatory signals, while Ipamorelin directly influences the release process at the pituitary level. This dual-stimulation pathway mechanism aids in studying the rhythmic characteristics and regulatory intensity of the growth hormone axis. This combination provides a critical model for exploring synergistic regulation in studies of metabolic modulation, endocrine feedback, and growth axis mechanisms.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv id=\"location_1750667616587\" data-type=\"locations\" data-level=\"rows\"\u003e\n\u003cdiv class=\"backstage-stwidgets-settingwrap\" scope=\"0\" id=\"component_yPKEnHFkjZhO\"\u003e\n\u003cdiv class=\"sitewidget-gallery sitewidget-proddetail sitewidget-162f6be7-60af-409f-a195-fbc2d9ed0d20-20250624132610 prod_des_sitewidget-162f6be7-60af-409f-a195-fbc2d9ed0d20-20250624132610\"\u003e\n\u003cdiv class=\"sitewidget-bd\"\u003e\n\u003cdiv class=\"detial-cont-divsions detial-cont-prodescription detial-cont-prodescription_pc prod_floating_mt\"\u003e\n\u003cdiv class=\"prod_describe_new3 prod_new_active3\" id=\"prod_describe_new_0\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTesamoreli\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eAs a synthetic growth hormone-releasing hormone (GHRH) analog, Tesamoreli demonstrates significant clinical value in the management of specific diseases. Its core therapeutic positioning is to intervene in the abnormal accumulation of abdominal fat in HIV-infected individuals caused by long-term antiretroviral therapy. This drug highly mimics the molecular action mode of endogenous GHRH, binds to the specific receptors on the surface of growth hormone cells in the anterior pituitary gland, activates the G protein-coupled signaling pathway, and then induces the pulsatile release of growth hormone (GH) from the anterior pituitary gland. With the continuous increase of GH concentration in the circulatory system, the synthesis process of insulin-like growth factor-I (IGF-I) in the liver and peripheral tissues is significantly activated. This key growth factor regulates the energy metabolism network of adipocytes - including enhancing the activity of lipolytic enzymes to promote visceral fat breakdown and inhibiting the expression of fatty acid synthase to reduce fat deposition - ultimately achieving the reconstruction of abnormal fat distribution and the reduction of abdominal fat load.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn addition to the fat-reducing effect on the target organs, the pharmacological effects of Tesamoreli generate multiple physiological benefits through the systemic regulation of the GH-IGF-I axis: at the level of body composition optimization, it promotes the amino acid uptake of skeletal muscle cells and activates the myofiber regeneration process mediated by satellite cells, maintaining or increasing the proportion of lean body mass, and thus having a positive regulatory effect on muscle strength. This effect is closely related to the enhanced protein synthesis and inhibited protein breakdown mediated by growth hormone; in the field of bone metabolism, this drug has a protective effect on bone mineral density through a dual mechanism of promoting the differentiation and maturation of osteoblasts and inhibiting the activity of osteoclasts, especially providing a potential intervention approach for the prevention of bone loss associated with chronic diseases. The above mechanisms of action indicate that Tesamoreli is not limited to the improvement of local fat accumulation but rather achieves the integrated regulation of the physiological functions of multiple systems throughout the body by targeting the endocrine metabolic axis.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_1\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e▎Ipamorelin\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eAs a synthetic pentapeptide compound, Ipamorelin, as an important member of the growth hormone secretagogue family, achieves precise regulation of the growth hormone secretion axis by virtue of its unique molecular structure design. This compound binds with high affinity to the growth hormone secretagogue receptor (GHS-R), activates the downstream signaling pathway, efficiently induces the pulsatile release of growth hormone (GH), and simultaneously promotes the gene expression and protein synthesis of insulin-like growth factor-1 (IGF-1). This dual mechanism of action not only regulates the energy metabolism process (including promoting amino acid uptake, accelerating protein synthesis, and optimizing fat catabolism) but also plays a positive regulatory role in tissue repair and growth by enhancing the cell proliferation signal.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn clinical studies, Ipamorelin has demonstrated multi-system regulatory effects. Its effect on improving gastrointestinal motility is manifested as accelerating the gastric emptying rate. Especially in the state of postoperative ileus, by promoting the peristaltic frequency and contraction intensity of gastrointestinal smooth muscles, it effectively relieves intestinal motor dysfunction. In the field of pain management, this compound regulates nociceptive signal transduction through both central and peripheral pathways and shows a significant relieving effect on non-inflammatory visceral pain and somatic pain. Its mechanism of action may involve the activation of the endogenous opioid peptide system and the regulation of ion channel activity.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eCompared with traditional growth hormone secretagogues, the significant advantage of Ipamorelin lies in its high selectivity for growth hormone release. While effectively stimulating GH secretion, this compound has no significant effect on the secretion of other pituitary-adrenal axis hormones such as adrenocorticotropic hormone (ACTH) and cortisol, thus reducing the risk of adverse reactions caused by hormonal disorders. This pharmacological property endows it with the potential for precise intervention in the replacement therapy of growth hormone deficiency, and at the same time provides a new drug target for the research on the pathogenesis of gastrointestinal motility disorders and the optimization of pain diagnosis and treatment programs.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_2\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e▎\u003c\/span\u003e\u003c\/strong\u003e\u003cstrong\u003eSummary\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e1. Growth Hormone Regulation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSynergistic Mechanism:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTesamoreli stimulates the secretion of growth hormone (GH) from the anterior pituitary gland by activating the growth hormone-releasing hormone (GHRH) receptor, while Ipamorelin promotes the pulsatile secretion of GH by selectively activating the growth hormone secretagogue receptor (GHSR).\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eWhen used in combination, the two can enhance the secretion of GH from different pathways, forming a synergistic effect and thus significantly increasing the level of GH in the body.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eBalance and Control of GH Secretion:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIpamorelin avoids the risk of excessive GH stimulation by mimicking the natural pulsatile secretion pattern of GH, while Tesamoreli provides a stable basis for GH secretion through the GHRH pathway. This combined use can maintain the GH level while ensuring the rhythmicity and balance of its secretion.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e2. Metabolic Optimization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eLipid Metabolism:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTesamoreli reduces visceral fat by enhancing fat breakdown and improving lipid metabolism, while Ipamorelin further accelerates fat metabolism by promoting fatty acid oxidation. When used in combination, the two can jointly optimize lipid metabolism, reduce age-related fat accumulation, and improve insulin sensitivity.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGlucose Metabolism:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTesamoreli reduces the risk of metabolic disorders by improving the efficiency of glucose utilization, while Ipamorelin protects muscle tissue and avoids energy loss through its anti-catabolic effect.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eThis synergistic effect helps maintain metabolic balance and supports healthy aging.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e3. Tissue Support and Repair\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProtein Synthesis and Cell Renewal:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTesamoreli promotes tissue repair and regeneration by stimulating protein synthesis and cell renewal, while Ipamorelin prevents muscle breakdown by protecting the existing tissue structure. When used in combination, the two can provide comprehensive tissue support, both promoting the repair of damaged tissues and protecting the existing tissues from being damaged.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAnti-aging Effect:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe increase in GH level is closely related to the anti-aging effect. The combined use of Tesamoreli and Ipamorelin can delay cell aging, improve skin elasticity, reduce wrinkles, and support bone health.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e4. Anti-aging and Cognitive Benefits\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNeuroprotection and Cognitive Function:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGH plays an important role in brain function and neuroprotection. The combined use of these two peptides can improve cognitive function and reduce age-related cognitive decline by regulating the GH level.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSystemic Resilience:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBy balancing GH secretion and optimizing metabolism, the combined use can enhance the systemic resilience of the body and support long-term health and functional capacity.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAbout The Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe above-mentioned materials are all researched, edited and compiled by Cocer Peptides.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_3\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_4\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"row\" data-type=\"rows\" data-level=\"rows\"\u003e\n\u003cdiv class=\"col-md-12 col-md-first col-md-last\" id=\"column_1750741485987\" data-type=\"columns\" data-level=\"columns\"\u003e\n\u003cdiv id=\"location_1750741485989\" data-type=\"locations\" data-level=\"rows\"\u003e\n\u003cdiv class=\"backstage-stwidgets-settingwrap\" id=\"component_zofEdwDNPUbt\" data-scope=\"0\" data-settingid=\"zofEdwDNPUbt\" data-relationcommonid=\"dUKAZpoOYViE\" data-classattr=\"sitewidget-placeHolder-20250623183551\"\u003e\n\u003cdiv class=\"sitewidget-placeholder sitewidget-placeHolder-20250623183551\"\u003e\n\u003cdiv class=\"sitewidget-bd\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267703529696,"sku":null,"price":220.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/d2a1a521-07e1-4190-95fd-0c011468843e.png?v=1782902032"},{"product_id":"cjc1295-ipamorelin-10-10-blend","title":"CJC1295,Ipamorelin 10\/10 (Blend)","description":"\u003cp\u003e\u003cspan\u003eThis combination is used for the synergistic regulation mechanism of the growth hormone axis. CJC-1295 prolongs the duration of endogenous growth hormone release signals, while Ipamorelin selectively stimulates growth hormone secretion. Mechanistically complementary, they act at distinct regulatory levels. Their combined use facilitates investigation of growth hormone secretion rhythms, feedback regulation, and endocrine system synergistic mechanisms. This combination holds significant experimental value for research into endocrine regulation and the growth axis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"prod_describe_new3 prod_new_active3\" id=\"prod_describe_new_0\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCJC1295 no DAC\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eAs a synthetic growth hormone-releasing hormone (GHRH) analog, the core mechanism of action of CJC1295 no DAC lies in its ability to significantly promote the endogenous secretion of growth hormone. By specifically binding to the corresponding receptor, this compound can not only effectively induce the pulsatile release of growth hormone, thus having a positive impact on the growth and repair process of muscle tissue, but also play a two-way regulatory role in the catabolism and anabolism of adipose tissue by regulating the energy metabolism pathway. At the same time, it can maintain and increase bone density by enhancing the activity of osteoblasts and inhibiting the function of osteoclasts.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eFrom the perspective of basic research and clinical application, these multiple biological effects make CJC1295 no DAC an important tool in the in-depth analysis of the growth hormone secretion mechanism. Especially in the field of diagnosis and treatment of growth hormone-related diseases, for endocrine disorders such as growth hormone deficiency and childhood short stature, its characteristic of promoting hormone secretion provides an experimental basis for exploring new treatment strategies. It is worth noting that for a series of aging-related phenotypes caused by the physiological decline of growth hormone with age, including decreased skeletal muscle mass, increased body fat percentage, and decreased skin elasticity, CJC1295 no DAC shows potential anti-aging biological effects by increasing the level of growth hormone in the circulatory system. This provides a new research direction for the intervention research of aging-related diseases and the application exploration of improving the quality of life of the elderly population.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn the fields of exercise physiology and sports science, this compound has a positive effect on the muscle growth, post-exercise recovery, and improvement of athletic performance of athletes through multiple pathways such as accelerating muscle protein synthesis, promoting muscle fiber repair, and enhancing energy metabolism efficiency. Thus, it has become an important focus in the research of strategies for enhancing athletic ability in the field of sports medicine. Overall, with its unique mechanism of action and extensive biological effects, CJC1295 no DAC shows important research value and application potential in multiple fields such as basic medical research, clinical disease treatment, and sports science.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_1\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e▎Ipamorelin\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIpamorelin is a synthetic pentapeptide compound. As an important member of the growth hormone secretagogue family, its molecular structure design endows it with the ability to precisely regulate the growth hormone secretion axis. This compound binds with high affinity to the growth hormone secretagogue receptor (GHS-R), activating the downstream signaling pathway, thus efficiently inducing the pulsatile release of growth hormone (GH) and simultaneously promoting the gene expression and protein synthesis of insulin-like growth factor-1 (IGF-1). This dual mechanism of action not only regulates the energy metabolism process (including promoting amino acid uptake, accelerating protein synthesis, and optimizing fat catabolism), but also plays a positive regulatory role in tissue repair and growth by enhancing the cell proliferation signal.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn clinical application research, Ipamorelin has shown multi-system regulatory effects: its effect on improving gastrointestinal motility is manifested as accelerating gastric emptying rate. Especially in the pathological state of postoperative ileus, it can effectively relieve intestinal motility disorders by promoting the peristaltic frequency and contraction intensity of gastrointestinal smooth muscles; in the field of pain management, this compound regulates nociceptive signal transmission through both central and peripheral pathways, showing a significant relieving effect on non-inflammatory visceral pain and somatic pain. Its mechanism of action may involve the activation of the endogenous opioid peptide system and the regulation of ion channel activity.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eCompared with traditional growth hormone secretagogues, the significant advantage of Ipamorelin lies in its high selectivity for growth hormone release - while effectively stimulating GH secretion, it has no significant effect on the secretion of other pituitary-adrenal axis hormones such as adrenocorticotropic hormone (ACTH) and cortisol, thus reducing the risk of adverse reactions caused by hormonal disorders. This pharmacological property gives it the potential for precise intervention in the replacement treatment of growth hormone deficiency, and at the same time provides a new drug target for the research on the pathogenesis of gastrointestinal motility disorders and the optimization of pain diagnosis and treatment programs. Currently, based on its unique mechanism of action and safety characteristics, the translational application research of Ipamorelin in the fields of endocrine diseases, digestive system diseases, and pain medicine is continuously deepening, showing broad clinical application prospects.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_2\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e▎\u003c\/span\u003e\u003c\/strong\u003e\u003cstrong\u003eSummary\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePromoting Muscle Growth and Repair:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe combined use of CJC1295 No DAC and Ipamorelin can significantly increase the synthesis of muscle proteins and accelerate the repair and regeneration of muscle tissue. Its mechanism of action may involve the direct stimulation of muscle cells by growth hormone, as well as the indirect promotion of muscle growth by regulating other growth factors and metabolic pathways. In the field of sports medicine, the combined application of these two peptide substances has important value. For fitness enthusiasts, it can promote muscle recovery after exercise, enhance muscle strength and volume, and improve training effects. Studies have shown that growth hormone can activate muscle stem cells, promoting their proliferation and differentiation into mature muscle cells, thus accelerating the muscle repair process.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOptimizing Fat Metabolism:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe combined use of Ipamorelin and CJC1295 No DAC can increase the level of growth hormone, thereby promoting the decomposition and oxidation of fat. Growth hormone can increase the activity of lipolytic enzymes in fat cells, promoting the decomposition of fat into free fatty acids and glycerol to provide energy for the body. At the same time, it can also improve the utilization efficiency of fat, reduce the storage of body fat, and improve body composition. This is of great significance for fat loss and body shaping, especially for those who want to reduce their body fat percentage and improve their body lines.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEnhancing Energy Levels and Athletic Performance:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe increase in growth hormone can increase the basal metabolic rate and enhance the efficiency of energy production and utilization. An increase in the basal metabolic rate means that the body can consume more energy even at rest, which helps to maintain the body's energy balance. This enables users to obtain higher energy levels during daily activities and exercise, extend exercise endurance, and improve athletic performance.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImproving Sleep Quality:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGrowth hormone plays an important role in regulating the sleep cycle and quality. The combined use of Ipamorelin and CJC1295 No DAC can improve the sleep structure and increase the deep sleep time. Deep sleep is crucial for the body's recovery and repair. It can promote the secretion of growth hormone, enhance the function of the immune system, and improve the cognitive ability of the brain.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEnhancing Immune Function:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGrowth hormone supports the normal function of the immune system. It can enhance the activity and function of immune cells, improve the body's immunity, and help resist diseases. By increasing the level of growth hormone, the combined use of Ipamorelin and CJC1295 No DAC can enhance the proliferation and differentiation ability of immune cells, promote the production of antibodies, and improve the body's resistance to pathogens.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e2. Application Fields\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAnti-aging Medicine:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWith the increase of age, the level of growth hormone in the human body gradually decreases, leading to aging phenomena such as muscle loss, fat gain, and skin relaxation. The combined use of Ipamorelin and CJC1295 No DAC can increase the level of growth hormone and has potential anti-aging effects. Researchers are exploring the application of these two peptide substances in delaying aging and improving the quality of life of the elderly. For example, they can be used to prevent and treat aging-related diseases such as senile muscle atrophy, osteoporosis, and cardiovascular diseases.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSports Medicine:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the sports field, the combined use of CJC1295 No DAC and Ipamorelin can promote muscle growth and repair, enhance athletic performance, and reduce the occurrence of sports injuries. Fitness enthusiasts can use these two peptide substances as an auxiliary means to improve training effects and accelerate the recovery process.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTreatment of Endocrine Diseases:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor endocrine diseases such as growth hormone deficiency and idiopathic short stature, the combined use of Ipamorelin and CJC1295 No DAC provides new ideas and methods for treatment. By regulating the secretion of growth hormone, it helps to improve the symptoms of patients and promote the normal development and growth of the body.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAbout The Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe above-mentioned materials are all researched, edited and compiled by Cocer Peptides.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267706839264,"sku":null,"price":260.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/5a24af61-53c0-4f6b-9847-595730888c7f.png?v=1782902151"},{"product_id":"bpc-157-40mg","title":"BPC 157 40mg","description":"\u003cp\u003e\u003cspan\u003eBPC-157 is a peptide fragment derived from the gastric mucosa-associated sequence, commonly used to study tissue protection and repair mechanisms. Its effects manifest in maintaining tissue integrity, supporting local repair responses, and promoting structural stability post-injury. Its mechanism involves the coordinated regulation of multiple signaling pathways, including cell survival, vascular-related signaling, and tissue repair pathways. In research, BPC-157 is employed to explore regulatory patterns across different tissue types during injury and recovery processes, holding significant value in studies of repair biology and tissue homeostasis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"prod_describe_new3 prod_new_active3\" id=\"prod_describe_new_0\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cspan\u003e\u003cstrong\u003eBpc 157 Overview\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eBpc 157 is a synthetic peptide composed of 15 amino acids, also known as \"Body Protection Compound 157\". It was initially isolated from the proteins in gastric juice and later artificially synthesized. Bpc 157 possesses multiple biological activities, including promoting wound healing, neuroprotection, anti-ulcer, anti-inflammatory, and antioxidant effects, among others.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn terms of promoting wound healing, Bpc 157 can accelerate the repair process of tissues such as the skin, tendons, and ligaments. It shows particularly remarkable effects in the healing of burn wounds. It promotes angiogenesis and tissue regeneration by enhancing the biological functions of endothelial cells, such as proliferation, migration, and tubule formation. Regarding neuroprotection, Bpc 157 can have a positive impact on the central nervous system by regulating neurotransmitters such as serotonin and dopamine, which helps to improve problems such as indigestion, malabsorption, and low immune function.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eBpc 157 also has anti-ulcer and anti-inflammatory properties. It can maintain the integrity of the gastrointestinal mucosa, preventing bacteria and toxins from entering and damaging the intestine. In addition, it plays a certain role in liver protection. It can prevent cell proliferation, protect the structure of liver cells, maintain normal enzyme levels, reduce inflammatory cytokines, and combat liver fibrosis.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eCompared with other drugs, the advantage of Bpc 157 lies in its lack of significant toxicity or side effects, and it exhibits good safety and tolerability in various animal models. It not only has unique advantages in the treatment of intestinal diseases but also may play an important role in promoting tissue repair, improving brain health, and anti-aging.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_1\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cspan\u003e\u003cstrong\u003e▎\u003c\/strong\u003e\u003cstrong\u003eBpc 157\u003c\/strong\u003e\u003cstrong\u003e Structure\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/c0777290-d819-4f2d-8287-7dbfdd739ed6.png?v=1782899749\" alt=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eSequence: GEPPPGKPADDAGLV\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C\u003csub\u003e62\u003c\/sub\u003eH\u003csub\u003e98\u003c\/sub\u003eN\u003csub\u003e16\u003c\/sub\u003eO\u003csub\u003e22\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp\u003eMolecular Weight: 1419.5g\/mol\u003c\/p\u003e\n\u003cp\u003eCAS Number: 137525-51-0\u003c\/p\u003e\n\u003cp\u003ePubChem CID: 9941957\u003c\/p\u003e\n\u003cp\u003eSynonyms: Bepecin\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eBpc 157 Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the research background of Bpc 157?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBpc 157 is a peptide composed of 15 amino acids and is part of the sequence of the body protection compound (Bpc) discovered and isolated from human gastric juice. The following is the research background related to Bpc 157:\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe Brain-Gut Axis and Bpc 157:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eBrain-gut interaction involves peptidergic growth factors. Among them, the stable gastric pentadecapeptide  Bpc 157 is an anti-ulcer peptidergic drug that is safe and effective in inflammatory bowel disease trials and is currently undergoing trials for multiple sclerosis. It naturally exists in human gastric juice\u003csup\u003e[1]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e. Bpc 157 may act as a new mediator of Robert cell protection, participating in maintaining the integrity of the gastrointestinal mucosa without toxic effects.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIt has achieved success in treating gastrointestinal diseases, periodontitis, liver and pancreatic lesions, as well as the healing of various tissues and wounds. It also stimulates the Egr-1 gene, NAB2, FAK-paxillin, and JAK-2 pathways\u003csup\u003e[1]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e.When Bpc 157 is administered peripherally, corresponding beneficial central effects are initially observed, especially changes in serotonin release in certain areas of the brain (mainly the nigrostriatal region). Bpc 157 regulates the serotonergic and dopaminergic systems, having a beneficial effect on various behavioral disorders that occur due to specific stimulation\/damage of the neurotransmitter system.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn addition, Bpc 157 has neuroprotective effects, such as protecting somatosensory neurons, promoting peripheral nerve regeneration, counteracting the progression process after traumatic brain injury, preventing axonal and neuronal necrosis, demyelination, and cyst formation in rats with spinal cord compression accompanied by caudal paralysis, and restoring caudal function\u003csup\u003e[1]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe Role in Gastric Cell Protection and Organ Protection:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eBpc 157 is of great significance as a possible mediator of Robert's gastric cell protection\/adaptive cell protection and organ protection, as well as a new mediator of Selye's stress response. Bpc 157 protects gastric cells and maintains the integrity of the stomach against various harmful substances.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIt can prevent the adverse effects of alcohol and non-steroidal anti-inflammatory drugs on the gastric epithelium and other epithelia (such as the skin, liver, pancreas, heart, and brain), and has potential applications in wound healing. In addition, Bpc 157 can also counteract gastric endothelial damage, protect other vascular endothelia, have a positive impact on blood vessels, rapidly reconstruct the integrity of blood flow, and counteract tumor cachexia, muscle wasting, and increased pro-inflammatory\/cachectic cytokines\u003csup\u003e[2]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe Therapeutic Role in Vascular Occlusion:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eIn the study of superior mesenteric artery and vein occlusion in rats, Bpc 157 can rapidly activate collateral pathways, including the superior mesenteric vein-inferior anterior pancreaticoduodenal vein-superior anterior pancreaticoduodenal vein-pyloric vein-portal vein pathway, alternative pathways to the inferior vena cava through the middle colic vein and inferior mesenteric vein, as well as the inferior anterior pancreaticoduodenal artery and inferior mesenteric artery.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eBpc 157 can counteract superior sagittal sinus, portal vein, and inferior vena cava hypertension, aortic hypotension, progressive venous and arterial thrombosis in the peripheral and central areas, alleviate multi-organ lesions, lesions in the heart, lungs, liver, kidneys, gastrointestinal tract, especially in the brain, and oxidative stress in tissues\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[3]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eThe Role in Budd-Chiari Syndrome: In the study of the Budd-Chiari syndrome model (occlusion of the suprahepatic vena cava) in rats, Bpc 157 can rapidly form bypass pathways of the inferior vena cava-azygos vein (hemiazygos vein)-superior vena cava and portacaval shunt, counteract portal vein and inferior vena cava hypertension, aortic hypotension, and alleviate thrombosis, electrocardiogram disorders, and lesions in the liver and gastrointestinal tract. During ligation, the levels of nitric oxide and malondialdehyde in the liver remain within the normal healthy value range, and the increase in serum enzymes is also significantly reduced\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[4]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe Potential Therapeutic Role in COVID-19: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCOVID-19 is regarded as a thrombotic and vascular disease mainly targeting systemic endothelial cells, which can cause central vascular dysfunction, leading to complications and multi-organ failure. Bpc 157 is a peptide that has anti-inflammatory, cytoprotective, and endothelial protective effects in different organ systems of different species. It can activate endothelial nitric oxide synthase, which is related to nitric oxide release, tissue repair, and vascular regulation properties, improve vascular integrity and immune response, reduce the pro-inflammatory state, and reduce the severity of the disease. Therefore, it is crucial to discuss its potential as a preventive and supplementary treatment method\u003csup\u003e[5]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e(Deek S A, 2022).\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the specific mechanism of action of Bpc 157 in the brain-gut axis?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe brain-gut axis is a complex two-way communication system involving the interaction between the nervous system and the gastrointestinal tract, and Bpc 157 plays an important role in it, mainly in three aspects: First, as a cytoprotective mediator, Bpc 157 can participate in maintaining the integrity of the gastrointestinal mucosa. As a new mediator of Robert cell protection without toxic effects, it maintains the normal physiological function of the gastrointestinal tract by protecting gastrointestinal cells, thereby affecting the balance of the brain-gut axis. Second, it regulates the neurotransmitter system. Bpc 157 can regulate the serotonergic and dopaminergic systems. When Bpc 157 is administered peripherally, the release of serotonin in specific brain areas (mainly the nigrostriatal region) will change, producing beneficial central effects. Moreover, it can beneficially affect various behavioral disorders that occur due to specific stimulation\/damage of the neurotransmitter system. For example, it regulates the serotonergic and dopaminergic systems to improve behavioral problems caused by abnormal neurotransmitter systems. Third, it has neuroprotective effects. Bpc 157 can protect somatosensory neurons, promote neuron survival and functional recovery in case of nerve injury, promote peripheral nerve regeneration, and restore nerve conduction function, reducing traumatic brain injury. For example, in the case of spinal cord compression in rats accompanied by caudal paralysis, axonal and neuronal necrosis, demyelination, and cyst formation, Bpc 157 can salvage caudal function and reduce the damage to organs such as the nervous system and gastrointestinal tract caused by drug overdose or encephalopathy, protecting the normal functions of the body\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the specific mechanism of Bpc 157 in treating central nervous system diseases?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBpc 157 has shown multiple potential mechanisms in treating central nervous system diseases. In the model of cerebral ischemic stroke, Bpc 157 effectively counteracts the stroke induced by bilateral common carotid artery clamping by protecting neurons and supporting specific gene expression. It can address the persistent damage to brain neurons in rats, while improving disturbed memory, motor, and coordination abilities. It has a direct protective effect on the neuronal damage caused by ischemic stroke and also supports the expression of specific genes in the hippocampal tissue. It may promote the survival and functional recovery of neurons by regulating the expression of specific genes\u003csup\u003e[6]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/2bed02dc-83ba-476a-9506-dfee33f78c8f.png?v=1782902768\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_2\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cem\u003eExamples of successful administration mechanisms for the delivery of BPC 157; all routes, local and systemic, have been reported to have positive healing outcomes\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eSource:PubMed\u003csup\u003e[7]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eFor schizophrenia, Bpc 157 regulates the relationship between the nitric oxide system and the dopamine system and counteracts various abnormalities of the dopamine system, thereby improving the symptoms of schizophrenia. It can address the complex relationship between the nitric oxide system and amphetamine, apomorphine, MK-801, and chronic methylphenidate administration, indicating that it may improve the symptoms of schizophrenia by regulating the functions of the nitric oxide system and the dopamine system. It can also counteract various abnormalities of the dopamine system, including dopamine receptor blockade, the development of receptor hypersensitivity, receptor activation, excessive release, nigrostriatal damage, and vesicular depletion, etc. It has a wide range of regulatory effects on the dopamine system and helps to restore the functional balance of the dopamine system in schizophrenia patients\u003csup\u003e[6]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn addition, as a new type of cytoprotective mediator, Bpc 157 regulates the serotonergic and dopaminergic systems, has a beneficial effect on behavioral disorders, and through its neuroprotective effect, protects somatosensory neurons, promotes peripheral nerve regeneration, counteracts the progression of traumatic brain injury, and restores caudal function. It may act as a new type of cytoprotective mediator, participate in maintaining the integrity of the gastrointestinal mucosa, and have an indirect therapeutic effect on central nervous system diseases. It can also regulate the serotonergic and dopaminergic systems, have a beneficial effect on various behavioral disorders that occur due to specific (excessive) stimulation\/damage of the neurotransmitter system, and at the same time have neuroprotective effects, such as protecting somatosensory neurons, promoting peripheral nerve regeneration, counteracting the progression of traumatic brain injury, counteracting axonal and neuronal necrosis, demyelination, and cyst formation in rats with spinal cord compression, and restoring caudal function\u003csup\u003e[1]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat are the Studies Related to Bpc 157?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAs a Potential Treatment for COVID-19: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn late 2019, coronavirus disease 2019 (COVID-19) triggered a large-scale pandemic worldwide. Research suggests that COVID-19 is largely a thrombotic and vascular disease targeting systemic endothelial cells, which can lead to the disruption of central vascular function\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[5]\u003c\/sup\u003e. Patients with COVID-19 may develop multi-organ failure such as acute respiratory distress syndrome, cardiovascular complications, liver injury, and nerve injury. Based on animal model data, researchers have discussed the role of Bpc 157 as a novel drug in improving the clinical management of COVID-19. Bpc 157 is a peptide that exhibits anti-inflammatory, cytoprotective, and endothelial protective effects in different organ systems of different species. Bpc 157 activates endothelial nitric oxide synthase (eNOS), which is related to nitric oxide (NO) release, tissue repair, and vascular regulation properties, and can improve vascular integrity and immune response, reduce the pro-inflammatory state, and reduce the severity of the disease. Therefore, it is of great significance to discuss its potential as a preventive and adjuvant treatment method.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAccelerating the Healing of Musculoskeletal Soft Tissue: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA review has been conducted on the role of Bpc 157 in the treatment of soft tissue injuries\u003csup\u003e[7]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e.Currently, all experiments studying Bpc 157 have shown that for various types of injuries (including traumatic and systemic injuries and a variety of soft tissue injuries), Bpc 157 has a consistent positive and rapid healing effect. However, to date, most of the studies have been conducted on small rodent models, and the efficacy of Bpc 157 has not been confirmed in humans. Nevertheless, Bpc 157 clearly has great potential and is expected to become a treatment method for the conservative treatment of low-vascular and low-cellular soft tissue (such as tendons and ligaments) injuries or as an adjuvant for recovery after further development. In addition, the skeletal muscle injury model shows that Bpc 157 not only has a beneficial effect on injuries caused by direct trauma but also on systemic injuries including hyperkalemia and hypermagnesemia.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImproving Motor Function after Spinal Cord Injury: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eResearchers have used a well-designed rat model to demonstrate that the stable gastric pentadecapeptide Bpc 157 can improve spinal cord injury\u003csup\u003e[8]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e. Previous studies have shown that Bpc 157 can counteract the consequences of peripheral (sciatic nerve) nerve transection\/anastomosis and improve nerve healing, brain trauma, and various encephalopathies. Bpc 157 has been used as an anti-ulcer peptide in inflammatory bowel disease trials and multiple sclerosis trials. In one study, rats received a single intraperitoneal injection of Bpc 157 (200 or 2μg\/kg) or normal saline (5ml\/kg) after spinal cord injury. All injured rats showed continuous improvement after Bpc 157 treatment, with significantly better clinical tail motor function and no self-mutilation behavior; the spasm problem was solved on the 15th day; under the microscope (starting from the 7th day), the vacuoles and axonal loss in the white matter, edema in the gray matter, and loss of motor neurons in Bpc 157 rats, as well as the reduction in the number of large myelinated axons in the rat caudal nerve, were largely counteracted. Electromyogram recordings showed a significant decrease in motor unit potentials in the tail muscles. In addition, researchers also conducted another experiment. Bpc 157 was administered 4 days after spinal cord injury, and Bpc 157 (10μg\/kg, 0.16μg\/mL, 12ml\/rat\/day) was given through drinking water for 4 weeks, while the control group received only drinking water. The results showed that the rats treated with Bpc 157 showed great improvement and continued to recover until complete recovery.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCounteracting Spinal Instability: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTo induce spinal instability in rats, researchers focused on bilateral facetectomy and explored the possible therapeutic benefits of the stable gastric pentadecapeptide Bpc 157 in drinking water\u003csup\u003e[9]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e.In previous studies, Bpc 157 has been shown to improve spinal cord injury, peripheral nerve injury, brain trauma, and various encephalopathies. In this study, rats received complete bilateral L3-L4 facetectomy, and after the operation, they were given Bpc 157 (10ng\/kg, 0.16ng\/mL, 12ml\/rat\/day) or only drinking water. Radiological evaluations were performed at week 1 and week 8. The results showed that at week 1, no obvious deformity was observed in the rats of the control group and the Bpc 157 group in any plane, the intervertebral disc space seemed to be unaffected, the neural foramen at the surgical level was slightly widened, and the rats in the Bpc 157 drinking group had a higher overall bone density. At week 8, no obvious deformity was observed in the rats of both groups in any plane, the intervertebral disc space was unaffected, the neural foramen at the surgical level was slightly widened, the rats in the Bpc 157 group had significantly higher bone density, and there was a lack of a large amount of callus formation in a random pattern visible in the control group. In addition, the rats in the control group showed obvious motor impairment immediately after injury induction, while the rats in the Bpc 157 drinking group completely counteracted this motor impairment.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn conclusion, the core value of Bpc 157 lies in its endogenous and multi-system regulatory characteristics, providing innovative solutions for refractory inflammation, tissue defects, and neuropsychiatric diseases. In the field of sports trauma, it can accelerate the repair and regeneration of tissues such as muscles, tendons, and ligaments, shorten the recovery time, and has a good therapeutic effect on acute trauma. In the treatment of burns, Bpc 157 can significantly enhance the biological functions of endothelial cells such as proliferation, migration, and tubule formation, thus accelerating the repair of burn wounds. In addition, it has a protective effect on the gastrointestinal tract, can promote the healing of gastrointestinal ulcers, and prevent and alleviate gastrointestinal diseases. Bpc 157 also shows potential in neuroprotection, protecting the nervous system through mechanisms such as reducing the inflammatory response and inhibiting apoptosis. It also has a protective effect on human organs such as the pancreas, liver, and heart, demonstrating its wide range of biological effects as a multifunctional peptide.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAbout The Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe above-mentioned materials are all researched, edited and compiled by Cocer Peptides.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eScientific Journal Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePredrag Sikiricis a scholar affiliated with multiple academic institutions, including the University of Zagreb, University of Sarajevo, Sch Med, University of JJ Strossmayer Osijek, and Rudjer Boskovic Institute. His research spans several disciplines such as Pharmacology \u0026amp; Pharmacy, Biochemistry \u0026amp; Molecular Biology, Gastroenterology \u0026amp; Hepatology, Physiology, and Cell Biology.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eSikiric's team has conducted extensive research on the cytoprotective effects of BPC157 in various organs and tissues, including its role in neural injury and gastrointestinal ulcers. He also holds patents for the development of BPC, a pharmacologically active substance, including its preparation methods and therapeutic applications.Sikiric Pis a respected figure in academia, and his research has significantly advanced the fields he is involved in. Sikiric Pis listed in the reference of citation [1].\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_3\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e▎\u003c\/span\u003eRelevant Citations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[1] Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications[J]. Current Neuropharmacology, 2016,14(8):857-865.DOI:10.2174\/1570159X13666160502153022.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[2] Sikiric P, Hahm K, Blagaic A B, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection\/Adaptive Cytoprotection\/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future[J]. Gut and Liver, 2020,14(2):153-167.DOI:10.5009\/gnl18490.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[3] Knezevic M, Gojkovic S, Krezic I, et al. Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157[J]. Biomedicines, 2021,9(7).DOI:10.3390\/biomedicines9070792.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[4] Gojkovic S, Krezic I, Vrdoljak B, et al. Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats.[J]. World Journal of Gastrointestinal Pathophysiology, 2020,11(1):1-19.DOI:10.4291\/wjgp.v11.i1.1.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[5] Deek S A. BPC 157 as Potential Treatment for COVID-19[J]. Medical Hypotheses, 2022,158.DOI:10.1016\/j.mehy.2021.110736.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[6] Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system[J]. Neural Regeneration Research, 2022,17(3):482.DOI:10.4103\/1673-5374.320969.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[7] Gwyer D, Wragg N M, Wilson S L. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing[J]. Cell and Tissue Research, 2019,377(2):153-159.DOI:10.1007\/s00441-019-03016-8.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[8] Perovic D, Krezic I, Dokuzovic S, et al. Stable Gastric Pentadecapeptide BPC 157 Recovers Motor Function After Rat Spinal Cord Injury[J]. Faseb Journal, 2019,33.https:\/\/doi.org\/10.1096\/fasebj.2019.33.1_supplement.822.5.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[9] Dokuzovic S, Bebek I, Perovic D, et al. Spinal Instability in Rats Counteracted by Pentadecapeptide BPC 157[J]. Faseb Journal, 2019,33.https:\/\/doi.org\/10.1096\/fasebj.2019.33.1_supplement.822.3.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267726893280,"sku":null,"price":260.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/264c8d79-bbc1-452b-949d-94fc07646446.png?v=1782902825"},{"product_id":"tb-500-20mg","title":"TB 500 20mg","description":"\u003cp\u003e\u003cspan\u003eTB500, a synthetic analog of Thymosin Beta-4 (Tβ4), promotes tissue repair and regeneration by regulating actin dynamics and stimulating cell migration, proliferation, and differentiation.TB500 is a functional fragment of thymosin β4 primarily used to study mechanisms related to cell migration and tissue repair. Its actions focus on promoting cell motility, supporting tissue structural reconstruction, and participating in repair signal regulation. Research indicates that TB500 is closely associated with cytoskeletal regulation, particularly influencing actin dynamics. Its mechanism enhances the coordination of tissue repair processes by modulating cell migration-related signaling pathways. TB500 holds significant research value in the fields of tissue regeneration, injury repair, and cell migration studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv id=\"prod_describe_new_0\" class=\"prod_describe_new3 prod_new_active3\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003eTB500, namely the synthetic analog of Thymosin Beta-4 (Tβ4), is a polypeptide with broad biological activities. By regulating the dynamic equilibrium of actin, it promotes cell migration, proliferation, and differentiation, thus playing a crucial role in tissue repair and regeneration.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eTB500 can accelerate the closure of skin wounds, increase collagen deposition, and reduce scar formation. Meanwhile, it alleviates the inflammatory response in diseases such as fatty liver and pulmonary fibrosis. Moreover, after a myocardial infarction, it protects cardiomyocytes, promotes neovascularization, and improves cardiac function.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn addition, TB500 features high efficiency, multifunctionality, and excellent biocompatibility. It can act directly on the damaged tissues, maximizing the therapeutic effect while reducing systemic exposure.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eAs a novel tool in regenerative medicine, TB500 provides new possibilities for the treatment of various diseases. Its potential in cardiovascular repair, neuroprotection, the treatment of eye diseases, and the management of chronic inflammation has made it a research hotspot in the field of regenerative medicine, driving the development of regenerative medicine towards more precise and efficient treatment approaches.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"prod_describe_new_1\" class=\"prod_describe_new3\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e▎TB500 Structure\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cimg alt=\"\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/b4dd2ec4-382c-40ec-b8af-563f36160ec4.png?v=1782902966\"\u003e\u003c\/p\u003e\n\u003cp\u003eSequence: LKKTETQ\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C\u003csub\u003e38\u003c\/sub\u003eH\u003csub\u003e68\u003c\/sub\u003eN\u003csub\u003e10\u003c\/sub\u003eO\u003csub\u003e14\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp\u003eMolecular Weight: 889.0 g\/mol\u003c\/p\u003e\n\u003cp\u003eCAS Number: 885340-08-9\u003c\/p\u003e\n\u003cp\u003ePubChem CID: 62707662\u003c\/p\u003e\n\u003cp\u003eSynonyms: QHK6Z47GTG\u003c\/p\u003e\n\u003cp\u003eSequence: LKKTETQ\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C\u003csub\u003e38\u003c\/sub\u003eH\u003csub\u003e68\u003c\/sub\u003eN\u003csub\u003e10\u003c\/sub\u003eO\u003csub\u003e14\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp\u003eMolecular Weight: 889.0 g\/mol\u003c\/p\u003e\n\u003cp\u003eCAS Number: 885340-08-9\u003c\/p\u003e\n\u003cp\u003ePubChem CID: 62707662\u003c\/p\u003e\n\u003cp\u003eSynonyms: QHK6Z47GTG\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTB500 Research\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the research background of TB500?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTB500 is a small peptide processed from the active site of thymosin β4. Thymosin β4 has the abilities of tissue regeneration, anti-inflammation, and rapid repair, and TB500 has inherited these properties as well. Initially, in the research on thymosin β4, it was found to possess multiple biological activities, playing important roles in aspects such as cell migration, tissue repair, and inflammation regulation. TB500 is the active fragment of thymosin β4. Researchers hope that through the study of TB500, they can gain a deeper understanding of its mechanism of action and explore whether it can be developed into a drug with specific therapeutic purposes.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn the fields of wound repair and tissue damage caused by chronic diseases, traditional treatment methods have certain limitations. Due to its potential ability in promoting cell migration and tissue repair, TB500 has become a research hotspot, and people expect it to provide new ideas and methods for treating these diseases. For example, in the research of diseases such as myocardial infarction and nerve injury, studies are carried out to explore whether TB500 can promote the repair of damaged tissues and the restoration of their functions.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eAthletes are prone to various injuries during training and competitions, including muscle strains and ligament injuries. TB500 is believed to potentially help accelerate injury repair and improve the recovery speed of sports injuries, so it has attracted attention in the field of sports medicine. Some studies attempt to explore the application potential of TB500 in the rehabilitation of athletes' injuries. However, at the same time, it has also triggered a controversy about whether it may be abused as a doping. With the development of medicine, the demand for new drugs is constantly increasing. As a peptide substance with a unique mechanism of action, TB500 has the potential to be developed into a new type of drug, providing more options for clinical treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the mechanism of action of TB500?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePromoting tissue regeneration:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eTB500 is a small peptide processed from the active site of thymosin β4. Thymosin β4 has the ability to promote tissue regeneration, and TB500 has inherited this property. It may promote tissue regeneration in the following ways:\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eActivating cell signaling pathways:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eIt may activate certain specific cell signaling pathways to promote cell proliferation and differentiation. For example, it may activate signaling pathways related to cell growth and repair, such as the PI3K\/Akt signaling pathway, etc., thereby stimulating cell proliferation and differentiation and promoting tissue regeneration\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRegulating the extracellular matrix:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eThe extracellular matrix plays an important role in tissue regeneration. TB500 may regulate the synthesis and degradation of the extracellular matrix, promoting cell adhesion, migration, and tissue remodeling. For example, it may increase the synthesis of collagen and elastin, improving the structure and function of tissues\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAnti-inflammatory effect:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eInflammation is a defensive response of the body to injury and infection, but excessive inflammation can lead to tissue damage. TB500 has an anti-inflammatory effect and can inhibit the production of inflammatory mediators. Inflammatory mediators such as cytokines and chemokines play a key role in the inflammatory response. TB500 may inhibit the production of these inflammatory mediators, thereby reducing the inflammatory response. For example, it may inhibit the production of inflammatory factors such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β)\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRegulating the function of immune cells:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eImmune cells play an important role in the inflammatory response. TB500 may regulate the function of immune cells, such as regulating the activity of macrophages and lymphocytes, thereby reducing the inflammatory response. For example, it may promote the transformation of macrophages into an anti-inflammatory phenotype and inhibit the activation and proliferation of lymphocytes\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAccelerating cell proliferation and differentiation:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eBy activating cell signaling pathways and regulating the extracellular matrix, TB500 can accelerate cell proliferation and differentiation, promoting the repair of damaged tissues\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReducing the inflammatory response: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe inflammatory response will delay tissue repair, and the anti-inflammatory effect of TB500 can reduce the inflammatory response, creating a favorable environment for tissue repair\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePromoting angiogenesis: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAngiogenesis is crucial for tissue repair. TB500 may promote angiogenesis, increasing the blood supply to damaged tissues, providing nutrients and oxygen for cells, and promoting tissue repair\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/d36eb461-ebf3-4b17-8f7e-743577499950.png?v=1782903016\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_2\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cem\u003eRegulation of MMP\/TIMP on hepatic fibrosis.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eSource:PubMed\u003csup\u003e[3]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHow does TB500 regulate the synthesis and degradation of the extracellular matrix?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe balance between the synthesis and degradation of the extracellular matrix (ECM) is essential for maintaining the normal structure and function of tissues. TB-500 may affect the synthesis of the extracellular matrix in the following ways:\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePromoting collagen deposition:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eTB-500 is believed to be able to promote collagen deposition, and collagen is an important component of the extracellular matrix. The specific mechanism of action may involve the regulation of cell signaling pathways involved in collagen synthesis. For example, it may promote the expression of collagen genes by activating certain growth factors or transcription factors, thereby increasing the synthesis of collagen\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePromoting endothelial cell differentiation and angiogenesis:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eEndothelial cells secrete a variety of extracellular matrix components during the process of blood vessel formation. TB-500 promotes endothelial cell differentiation and angiogenesis in dermal tissues, which may indirectly promote the synthesis of the extracellular matrix. The newly formed blood vessels require the support of the extracellular matrix, which may stimulate cells to synthesize more extracellular matrix components\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eInfluence on the degradation of the extracellular matrix:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIt may regulate the activities of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs):\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eThe degradation of the extracellular matrix is mainly regulated by matrix metalloproteinases and their inhibitors. Although there is currently no direct evidence that TB-500 regulates the activities of MMPs and TIMPs, considering that TB-500 has the effects of promoting cell migration and wound healing, and the processes of cell migration and wound healing are usually accompanied by the remodeling of the extracellular matrix, this may involve the regulation of MMPs and TIMPs. For example, in the study of liver fibrosis, matrix metalloproteinases and their specific inhibitors (i.e., tissue inhibitors of metalloproteinases, TIMPs) play a key role in collagen synthesis and dissolution. By restoring the balance between MMPs and TIMPs, the accumulation of the extracellular matrix can be inhibited, thereby reducing liver fibrosis\u003csup\u003e[3]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIndirectly regulating the degradation of the extracellular matrix by affecting cell behavior:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eTB-500 can promote keratinocyte migration. During the process of cell migration, cells need to regulate the degradation of the extracellular matrix to clear the way. This may involve the secretion of certain enzymes or factors by cells to regulate the degradation of the extracellular matrix. For example, in some physiological and pathological processes, cells secrete matrix metalloproteinases to degrade the extracellular matrix for migration\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIn what ways does TB500 interact with biomaterials to promote muscle regeneration?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRelease of bioactive molecules:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eBiomaterials can serve as carriers and act in concert with TB500 to release bioactive molecules, promoting muscle regeneration. For example, some biomaterials can release active substances such as growth factors. These substances work together with TB500 to stimulate the proliferation and differentiation of muscle cells. TB500 itself has the effects of promoting cell migration and angiogenesis. Combined with the active molecules released by biomaterials, it can more effectively promote muscle regeneration\u003csup\u003e[4, 5]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe role of biomimetic materials:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eBiomimetic materials mimic the natural structure and function of muscle tissues, providing a suitable microenvironment for TB500. Such biomimetic materials can be better compatible with muscle tissues, promoting the action of TB500 at the damaged site. For example, biomimetic materials with a specific pore structure can provide support for cell growth, and at the same time, allow TB500 to diffuse and function better\u003csup\u003e[4]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImmunomodulatory effect:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eBiomaterials can promote muscle regeneration by regulating the immune system, in coordination with TB500. Studies have shown that biomaterials can regulate the polarization of macrophages, thereby controlling the immune response and creating a favorable environment for muscle regeneration. TB500 may further enhance this immunomodulatory effect by affecting the activity of immune cells. For example, through the immunomodulation mediated by biomaterials, the polarization of macrophages can be regulated to promote the soft tissue regeneration of the musculoskeletal system, and TB500 may play a synergistic role in this process\u003csup\u003e[5]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCombination of stem cells and biomaterials:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eStem cells play an important role in muscle regeneration. Combining with biomaterials and TB500 can provide a more effective treatment strategy. Many stem cell populations, such as mesenchymal stem cells and adipose-derived stem cells, are involved in muscle regeneration. Biomaterials can provide support and guidance for stem cells, while TB500 can promote the migration, survival, and differentiation of stem cells. The combination of the three can overcome the limitations of using them alone and promote muscle regeneration.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePromotion of nerve regeneration: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePeripheral nerve regeneration also plays a key role in muscle regeneration. Biomaterials can provide structural bridging to promote nerve regeneration, and TB500 may further promote nerve regeneration and muscle function recovery by affecting the gene expression related to neurogenesis. For example, some studies have found that the gene arrays related to neurogenesis are upregulated, suggesting the role of peripheral nerve regeneration in mediating the recovery of muscle force, and biomaterials and TB500 may jointly promote this process\u003csup\u003e[6]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eApplication of magnetically responsive biomaterials:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eNew magnetically responsive biomaterials can enhance muscle regeneration by triggering drug and cell delivery. TB500 can be used in combination with such biomaterials to improve the repair effect of damaged muscles. For example, a biphasic iron gel scaffold can be used to deliver cells and growth factors, precisely timing in vivo to enhance functional muscle regeneration during inflammation. TB500 may act synergistically with this biomaterial to further promote muscle regeneration\u003csup\u003e[7]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eOverall, as a small peptide processed from the active site of thymosin β4, TB500 has shown remarkable potential in tissue regeneration, anti-inflammation, and rapid repair. Research has found that it can promote endothelial cell differentiation, angiogenesis, and keratinocyte migration, and may also regulate the synthesis and degradation of the extracellular matrix. In the field of muscle repair, TB500 may bring new hope for the repair of sports injuries by promoting the proliferation and differentiation of muscle stem cells, regulating the inflammatory response, and interacting with biomaterials. TB500 has the potential to become an effective drug for the adjuvant treatment of tissue damage and related diseases.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAbout The Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe above-mentioned materials are all researched, edited and compiled by Cocer Peptides.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eScientific Journal Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYe J is a researcher at Zhejiang University and a member of the Orthopedic Regenerative Medicine Group (CORMed). His research areas include engineering, materials science, automation and control systems, business and economics, and mathematical methods in social sciences. Ye J has been involved with various academic institutions and organizations, such as Opt Clearing Corp, CTC Holdings, University of Illinois Chicago, and Dalian Institute of Chemical Physics, CAS. Ye J is listed in the reference of citation [5].\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_3\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e▎\u003c\/span\u003eRelevant Citations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[1] Rahaman K, Muresan A, Son J, et al. Development of analytical methods for TB-500 and its metabolites by LC-MS\/MS[M]. 2022.10.13140\/RG.2.2.32176.02564.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[2] Ho E N M, Kwok W H, Lau M Y, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry[J]. Journal of Chromatography A, 2012,1265:57-69.DOI:10.1016\/j.chroma.2012.09.043.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[3] Shan L, Wang F, Zhai D, et al. Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis[J]. Biomedicine \u0026amp; Pharmacotherapy, 2023,161.DOI:10.1016\/j.biopha.2023.114472.\u003c\/p\u003e\n\u003cp\u003e[4] Carleton M M, Sefton M V. Promoting endogenous repair of skeletal muscle using regenerative biomaterials[J]. Journal of Biomedical Materials Research Part A, 2021,109(12):2720-2739.DOI:10.1002\/jbm.a.37239.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[5] Ye J, Xie C, Wang C, et al. Promoting musculoskeletal system soft tissue regeneration by biomaterial-mediated modulation of macrophage polarization[J]. Bioactive Materials, 2021,6(11):4096-4109.DOI:10.1016\/j.bioactmat.2021.04.017.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[6] Roberts K, Kim J T, Huynh T, et al. Transcriptome profiling of a synergistic volumetric muscle loss repair strategy[J]. Bmc Musculoskeletal Disorders, 2023,24(1).DOI:10.1186\/s12891-023-06401-1.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[7] Cezar C A. Magnetically Responsive Biomaterials for Enhanced Skeletal Muscle Regeneration[M]. 2015.https:\/\/www.proquest.com\/dissertations-theses\/magnetically-responsive-biomaterials-enhanced\/docview\/1761573755\/se-2.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267731480800,"sku":null,"price":320.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/bdda1a03-c3dc-4ac1-ac0f-e897e11ac32e.png?v=1782903089"},{"product_id":"epitalon-50mg","title":"Epitalon 50mg","description":"\u003cp\u003e\u003cspan\u003eEpitalon is a short peptide composed of four amino acids, initially studied for its role in cellular aging and circadian rhythm mechanisms. Its primary functions focus on cellular renewal, regulation of the cell cycle, and maintenance of overall homeostasis. Research indicates that Epitalon participates in intracellular signaling pathways, exerting regulatory effects on the cellular life cycle. Its mechanisms involve telomere-related regulation, rhythmic gene expression, and the stability of cell cycle signaling. By influencing key regulatory pathways, it contributes to the long-term functional maintenance of cells. In studies of aging mechanisms, circadian rhythm regulation, and cellular homeostasis, Epitalon is regarded as a significant research tool, holding fundamental importance for understanding long-term regulation at the cellular level.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"prod_describe_new3 prod_new_active3\" id=\"prod_describe_new_0\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cspan\u003e\u003cstrong\u003eWhat is Epitalon?\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eEpitalon is a synthetic tetrapeptide. It is an anti-aging drug and a telomerase activator. It has an inhibitory effect on the development of spontaneous tumors in mice and also has the function of preventing aging. When administered nasally, it can increase the activity of neurons. It can also be used in the treatment of cancer, geriatric diseases, and retinitis pigmentosa.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eEpitalon helps cells replicate telomeres by activating telomerase, thus maintaining the health and replication ability of cells. This is of great significance for anti-aging and maintaining tissue function. In addition, Epitalon can also regulate the circadian rhythms of melatonin and cortisol, which may be helpful for improving sleep and maintaining the normal function of the biological clock.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn medical research, Epitalon has shown potential in many aspects, including extending the lifespan of experimental animals and improving visual function. As a polypeptide substance, Epitalon has broad application prospects in the fields of anti-aging, regenerative medicine, and the treatment of chronic diseases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_1\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cspan\u003e\u003cstrong\u003e▎\u003c\/strong\u003e\u003cstrong\u003eEpitalon\u003c\/strong\u003e\u003cstrong\u003e Structure\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/09aa5131-ccab-4436-9b88-8c47b88f8e60.png?v=1782903410\" alt=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eSequence: Ala-Glu-Asp-Gly\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C\u003csub\u003e14\u003c\/sub\u003eH\u003csub\u003e22\u003c\/sub\u003eN\u003csub\u003e4\u003c\/sub\u003eO\u003csub\u003e9\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp\u003eMolecular Weight: 390.35 g\/mol\u003c\/p\u003e\n\u003cp\u003eCAS Number: 307297-39-8\u003c\/p\u003e\n\u003cp\u003ePubChem CID: 219042\u003c\/p\u003e\n\u003cp\u003eSynonyms: Epithalon\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEpitalon\u003c\/strong\u003e\u003cstrong\u003e\u003cspan\u003e \u003c\/span\u003eResearch\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the research background of Epitalon?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the 1980s, a group of Russian researchers led by Vladimir Khavinson first discovered Epitalon1\u003csup\u003e[1]\u003c\/sup\u003e. Epitalon is a synthetic short peptide composed of four amino acids: alanine, glutamic acid, aspartic acid, and glycine. Its synthesis is based on the natural peptide epithalamion extracted from the pineal gland. Epitalon is believed to have antioxidant effects comparable to those of melatonin and may have the benefit of extending lifespan\u003csup\u003e[2]\u003c\/sup\u003e. Researchers have found that Epitalon can stimulate the activity of telomerase. Telomerase is an enzyme that can protect and extend the telomeres at the ends of chromosomes. As people age, telomeres shorten, which is associated with age-related diseases and a shorter lifespan. By stimulating telomerase activity, Epitalon may help extend telomeres, thereby slowing down the aging process and preventing aging-related diseases\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[1]\u003c\/sup\u003e. Some studies have shown that Epitalon may be involved in regulating the expression of CCL11 and HMGB1 genes and act as an activator of the expression of these genes. At the same time, the dipeptide vilon (Lys-Glu) and the tetrapeptide Epitalon (Ala-Glu-Asp-Gly) may exert their anti-aging effects by inhibiting these genes. Together, Epitalon and vilon are known to regulate gene expression and protein synthesis, promoting a reduction in mortality and a slowdown in pathological development in the elderly\u003csup\u003e[3]\u003c\/sup\u003e. Currently, the research on Epitalon mainly focuses on the animal experiment stage, and its long-term effectiveness and safety in humans have not been fully determined. Although some animal studies have achieved encouraging results, such as in rodents, Epitalon is associated with a longer lifespan and better health, the applicability of these results in humans still requires further research\u003csup\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the mechanism of action of Epitalon in the field of anti-aging?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReducing the level of reactive oxygen species: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReactive oxygen species (ROS) play an important role in the aging process of oocytes. Excessive ROS will cause oxidative damage to oocytes, affecting their quality and developmental potential. Studies have shown that Epitalon can reduce the rate of cytoplasmic fragmentation of oocytes caused by aging and the content of intracellular reactive oxygen species\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[2]\u003c\/sup\u003e. As an antioxidant, Epitalon can neutralize intracellular ROS and reduce its damage to oocytes. Specifically, it may be achieved in the following two ways: First, directly scavenging ROS. Epitalon may have the ability to directly react with ROS and convert it into harmless substances. Second, enhancing the activity of antioxidant enzymes. Epitalon may stimulate the activity of intracellular antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), etc. These enzymes can help scavenge ROS and maintain the intracellular redox balance.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImproving mitochondrial function: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMitochondria play a key role in the energy metabolism and cell survival of oocytes. As oocytes age, mitochondrial function will gradually decline, manifested as a decrease in mitochondrial membrane potential and a reduction in the copy number of mitochondrial DNA. Epitalon can increase the mitochondrial membrane potential and the copy number of mitochondrial DNA\u003csup\u003e[2]\u003c\/sup\u003e. This helps to improve the energy supply of oocytes and maintain the normal physiological functions of cells. The specific mechanism of action may include: First, increasing the mitochondrial membrane potential. Maintaining the mitochondrial membrane potential is crucial for the normal function of mitochondria. Epitalon may increase the mitochondrial membrane potential by regulating the ion channels or transport proteins on the mitochondrial membrane, enhancing the energy production capacity of mitochondria. Second, increasing the copy number of mitochondrial DNA. Increasing the copy number of mitochondrial DNA can improve the synthesis ability of mitochondria and provide more energy for cells. Epitalon may increase the copy number of mitochondrial DNA by promoting the replication of mitochondrial DNA or reducing its degradation.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReducing abnormal spindle morphology and abnormal exocytosis of cortical granules:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eDuring the aging process of oocytes, the ratios of abnormal spindle morphology and abnormal exocytosis of cortical granules will increase, which will affect the fertilization and embryonic development ability of oocytes. Epitalon can reduce the ratios of abnormal spindle morphology and abnormal exocytosis of cortical granules\u003csup\u003e[2]\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003e. This may be due to the regulatory effect of Epitalon on the stability of the cytoskeleton and the cell membrane: First, stabilizing the spindle structure. The spindle is an important structure in the process of cell division, and its abnormal morphology will lead to abnormal chromosome segregation and affect the development of oocytes. Epitalon may stabilize the spindle structure by regulating the polymerization and depolymerization of tubulin, reducing the occurrence of abnormal morphology. Second, maintaining the stability of cortical granules. Cortical granules play an important role in the fertilization process of oocytes. Epitalon may maintain the stability of cortical granules by regulating the permeability of the cell membrane or calcium ion signaling, reducing the occurrence of abnormal exocytosis.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReducing apoptosis signals:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eDuring the aging process of oocytes, apoptosis signals will increase, leading to cell death. Epitalon can reduce the positive rate of Annexin V staining and the fluorescence intensity of γH2AX in in vitro aged oocytes\u003csup\u003e[2]\u003c\/sup\u003e. This indicates that Epitalon can reduce the apoptosis of oocytes. The specific mechanism may include: First, inhibiting the apoptosis signaling pathway. Epitalon may inhibit the transmission of apoptosis signals by regulating key proteins in the apoptosis signaling pathway, such as Bcl-2 family proteins and caspase family proteins, and reduce cell death. Second, maintaining genomic stability. γH2AX is one of the markers of DNA damage. Epitalon may maintain genomic stability by reducing DNA damage and reducing apoptosis signals.\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/12519869-c5cd-41d7-a6fc-158308a267f5.png?v=1782903435\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cdiv id=\"location_1750667616587\" data-type=\"locations\" data-level=\"rows\"\u003e\n\u003cdiv class=\"backstage-stwidgets-settingwrap\" scope=\"0\" id=\"component_yPKEnHFkjZhO\"\u003e\n\u003cdiv class=\"sitewidget-gallery sitewidget-proddetail sitewidget-162f6be7-60af-409f-a195-fbc2d9ed0d20-20250624132610 prod_des_sitewidget-162f6be7-60af-409f-a195-fbc2d9ed0d20-20250624132610\"\u003e\n\u003cdiv class=\"sitewidget-bd\"\u003e\n\u003cdiv class=\"detial-cont-divsions detial-cont-prodescription detial-cont-prodescription_pc prod_floating_mt\"\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_2\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cem\u003eEpitalon maintained normal spindle integrity and CGs distribution.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eSource:PubMed\u003csup\u003e[2]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the specific mode of action of Epitalon in the treatment of neurodegenerative diseases?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRegulation of immune function: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStudies have shown that Epitalon can affect the immune response of mice under different stress conditions. In the face of immune-stimulating rotational stress and immunosuppressive combined stress, Epitalon can increase the proliferation activity of thymocytes\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[4]\u003c\/sup\u003e. This means that Epitalon may enhance the body's resistance to neurodegenerative diseases by regulating the immune system. The proliferation of thymocytes is closely related to the function of the immune system, and the immune system plays an important role in the occurrence and development of neurodegenerative diseases. For example, some neurodegenerative diseases may be related to the abnormal activation or dysfunction of the immune system. The promoting effect of Epitalon on the proliferation of thymocytes may help maintain the balance of the immune system, thereby alleviating the symptoms of neurodegenerative diseases.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eInfluence on the signal transduction pathway: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEpitalon has a regulatory effect on the interleukin-1β (IL-1β) signal transduction pathway. Specifically, Epitalon can increase the synergistic effect of IL-1β and affect the activity of the key enzyme in the ceramide signal transduction pathway in the cerebral cortex membrane, namely membrane neutral sphingomyelinase (nSMase)\u003csup\u003e[4]\u003c\/sup\u003e. IL-1β is an important cytokine involved in a variety of physiological and pathological processes. In neurodegenerative diseases, the abnormal expression of IL-1β may lead to neuroinflammation and neuronal damage. By regulating the IL-1β signal transduction pathway, Epitalon may reduce neuroinflammation and protect neurons from damage. In addition, changes in the activity of nSMase are also related to neurodegenerative diseases. The regulation of the activity of nSMase by Epitalon may help maintain the normal function of nerve cells.In conclusion, the mode of action of Epitalon in the treatment of neurodegenerative diseases may involve immune regulation and the regulation of the signal transduction pathway. However, the current research on Epitalon in the treatment of neurodegenerative diseases is still in the preliminary stage, and further research is needed to confirm its effectiveness and safety.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe research progress of Epitalon\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe impact on the quality of oocytes\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDelaying the aging of oocytes: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn vitro experimental studies have found that Epitalon can reduce the level of intracellular reactive oxygen species (ROS) in aged mouse oocytes after ovulation. Over time, the developmental potential of oocytes will gradually decrease after ovulation in vivo or in vitro. As a synthetic short peptide, Epitalon acts similarly to melatonin and is an effective antioxidant, which may have the benefit of extending lifespan. Treatment with Epitalon significantly reduced the frequency of spindle defects and abnormal distribution of cortical granules during 12 hours and 24 hours of aging, and at the same time increased the mitochondrial membrane potential and the copy number of mitochondrial DNA, thereby reducing the apoptosis of oocytes during 24 hours of in vitro aging. These results indicate that Epitalon can delay the aging process of oocytes in vitro by regulating mitochondrial activity and ROS levels\u003csup\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImproving the quality of oocytes: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdding 0.1 mM of Epitalon to the in vitro culture medium can reduce the rate of cytoplasmic fragmentation in the parthenogenetic activation of oocytes caused by in vitro aging after ovulation, reduce the ratios of abnormal spindle morphology and abnormal exocytosis of cortical granules, increase the mitochondrial membrane potential and the copy number of mitochondrial DNA, and reduce the positive rate of Annexin V staining and the fluorescence intensity of γH2AX in in vitro aged oocytes. This indicates that Epitalon can improve the disorder of organelles during the in vitro aging process of oocytes and improve the quality of oocytes (Xue Yue).\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe impact on the differentiation of nerve cells\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStudies have found that the AEDG peptide (Epitalon) can increase the synthesis of neurogenic differentiation markers in human gingival mesenchymal stem cells, such as Nestin, GAP43, β Tubulin III, and Doublecortin. Molecular modeling methods show that Epitalon preferentially binds to H1\/6 and H1\/3 histones, which may be one of the mechanisms for increasing the transcription of these neuronal differentiation genes\u003csup\u003e[5]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe regulatory effect on the nervous system\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRegulating neuronal activity:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eThrough research on rats, it has been found that intranasal infusion of Epitalon (2 ng) can significantly activate the neural activity of the cerebral cortex of rats within a few minutes, and the firing frequency of neurons is increased by 2 - 2.5 times\u003csup\u003e[6]\u003c\/sup\u003e. In some recordings, complex responses consisting of several stages were also observed. The increase in the spontaneous activity of neurons by Epitalon is caused by a higher frequency of already active units and the participation of previously silent cells. At least the first stage of the action of Epitalon can be explained by the direct effect of this peptide on the cells of the motor cortex.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eStress protection effect:\u003c\/strong\u003e \u003c\/p\u003e\n\u003cp\u003eEpitalon has a stress protection effect on mice exposed to different stress conditions. Experiments have shown that Epitalon increases the proliferation activity of thymocytes. Whether it is enhanced under immune-stimulating rotational stress or inhibited under immunosuppressive combined stress, Epitalon can play a regulatory role (Vladimir Kh Khavinson, 2002). At the same time, Epitalon can also increase the synergistic effect of interleukin-1β (IL-1β) and has an impact on the changes in the activity of sphingomyelinase (nSMase) in the cerebral cortex membrane induced by stress. This indicates that Epitalon has a stress protection effect at the level of IL-1β signal transduction in the sphingomyelin pathway and at the level of target thymocyte proliferation in nerve tissues.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe impact on the endocrine function of non-human primates: \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn elderly rhesus monkeys, Epitalon can reduce the basal levels of glucose and insulin and increase the basal nighttime melatonin level. At the same time, Epitalon can reduce the area under the plasma glucose response curve, increase the \"disappearance\" rate of glucose, and normalize the plasma insulin kinetics in response to the administration of glucose. This indicates that Epitalon is a promising factor for restoring age-related endocrine dysfunction in primates\u003csup\u003e[7]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe potential application of Epitalon in the treatment of nervous system diseases\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlzheimer's disease: Alzheimer's disease is a common neurodegenerative disease, mainly characterized by a decline in cognitive function and memory loss. Current research shows that Alzheimer's disease is related to impaired neurogenic differentiation. The number of neural stem cells in the brains of Alzheimer's disease patients decreases, and their differentiation ability is also inhibited. Epitalon may promote the proliferation and differentiation of neural stem cells, increase the number of neurons, and improve the cognitive function of Alzheimer's disease patients. In addition, Epitalon may also regulate the release of neurotransmitters, improving the memory and learning ability of Alzheimer's disease patients\u003csup\u003e[8]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eParkinson's disease: Parkinson's disease is a neurodegenerative disease mainly characterized by motor disorders. Its main pathological feature is the loss of dopaminergic neurons in the substantia nigra. The current treatment methods mainly relieve the symptoms by supplementing dopamine or inhibiting the degradation of dopamine, but these methods cannot stop the progression of the disease. Neural stem cell transplantation is a potential treatment method, but the source and differentiation ability of neural stem cells are still a problem. Epitalon may promote the proliferation and differentiation of neural stem cells, increase the number of dopaminergic neurons, and improve the motor function of Parkinson's disease patients\u003csup\u003e[8]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eStroke and brain injury: Stroke is a common cerebrovascular disease, and its main consequence is the death of neurons and neurological dysfunction. Brain injury may also lead to the loss of neurons and dysfunction. Neural stem cells play an important role in the repair and regeneration after stroke and brain injury. Epitalon may promote the proliferation and differentiation of neural stem cells, increase the number of neurons, and improve the neurological function of stroke and brain injury patients\u003cspan\u003e \u003c\/span\u003e\u003csup\u003e[8]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eIn conclusion, as a synthetic tetrapeptide, the core anti-aging mechanism of Epitalon lies in activating the expression of the telomerase reverse transcriptase subunit (TERT) gene, extending the length of telomeres and maintaining telomerase activity, thereby intervening in the core process of cellular aging. Its significance lies in the first realization of anti-aging intervention from the perspective of telomere biology, breaking through the limitation of traditional antioxidants that only target free radicals, and providing a new target for delaying age-related diseases such as Alzheimer's disease and cardiovascular diseases. Although its long-term safety (especially the risk of cancer) still needs to be verified in phase III clinical trials, as the research and development paradigm of the first telomerase activator-type anti-aging drug, it marks a revolutionary breakthrough in aging intervention from symptom improvement to molecular mechanism regulation and is expected to promote the extension of human healthy lifespan.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAbout The Author\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe above-mentioned materials are all researched, edited and compiled by Cocer Peptides.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eScientific Journal Author\u003c\/strong\u003eVladimir Khavinson is a prominent Russian biogerontologist and peptide bioregulator researcher. He is the Director of the St. Petersburg Institute of Bioregulation and Gerontology and a member of the Russian Academy of Medical Sciences. Khavinson has made significant contributions to the field of aging research and has authored numerous publications in reputable journals such as \"Molecular Biology of Aging\" and \"Journal of Anti-Aging Medicine\". His work primarily focuses on the development and application of peptide bioregulators to combat age-related diseases and improve healthspan. Khavinson's research has been influential in the field of gerontology, offering new insights and therapeutic approaches for healthy aging. Vladimir Khavinson is listed in the reference of citation [5].\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_3\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e▎\u003c\/span\u003eRelevant Citations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[1] Teterin O, Gv S. Epitalon[Z]. 2023. https:\/\/www.researchgate.net\/publication\/370060637_Epitalon\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[2] Yue X, Liu S, Guo J, et al. Epitalon protects of against post-ovulatory aging-related damage of mouse oocytes\u003cspan\u003e \u003c\/span\u003e\u003cem\u003ein vitro\u003c\/em\u003e[J]. Aging-Us, 2022,14(7):3191-3202. DOI: 10.18632\/aging.204007\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[3] Khavinson V K, Kuznik B I, Tarnovskaia S I, et al. Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data[J]. Advances in Gerontology = Uspekhi Gerontologii, 2014,27(3):399-406. DOI:10.1134\/S2079057015030078\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[4] Khavinson V K, Korneva E A, Malinin V V, et al. Effect of epitalon on interleukin-1β signal transduction and the reaction of thymocyte blast transformation under stress[J]. Neuroendocrinology Letters, 2002,23(5-6):411-416.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[5] Khavinson V, Diomede F, Mironova E, et al. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism[J]. Molecules, 2020,25(3).DOI:10.3390\/molecules25030609.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[6] Sibarov D A, Vol'Nova A B, Frolov D S, et al. Intranasal epitalon infusion modulates neuronal activity in the rat neocortex.[J]. Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova, 2006,92(8):949-956. https:\/\/pubmed.ncbi.nlm.nih.gov\/17217245\/\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[7] Goncharova N D, Vengerin A A, Khavinson V K, et al. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas[J]. Experimental Gerontology, 2005,40(1-2):51-57.DOI:10.1016\/j.exger.2004.10.004.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e[8] Zhou H, Wang B, Sun H, et al. Epigenetic Regulations in Neural Stem Cells and Neurological Diseases[J]. Stem Cells International, 2018,2018.DOI:10.1155\/2018\/6087143.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod_describe_new3\" id=\"prod_describe_new_4\"\u003e\n\u003cdiv class=\"prod_describe_new_content\"\u003e\n\u003cdiv class=\"prodDetail-editor-container sliderTable\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267737968864,"sku":null,"price":260.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/2f26fad4-31cb-4fde-87f4-06d6a40321ec.png?v=1782903507"},{"product_id":"na-selank-50mg","title":"NA Selank 50mg","description":"\u003cp\u003e\u003cspan\u003eNA Selank 50 mg is indicated for higher-dose neuromodulation studies. It influences central nervous system homeostasis by regulating neuropeptide signaling and GABA pathways. Research into its mechanism aids in understanding the dose-dependent characteristics of emotional regulation and neural balance, holding significant research value in the field of neuroscience.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eWhat is NA Selank?\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eNA Selank 50 mg is indicated for higher-dose neuromodulation studies. It influences central nervous system homeostasis by regulating neuropeptide signaling and GABA pathways. Research into its mechanism aids in understanding the dose-dependent characteristics of emotional regulation and neural balance, holding significant research value in the field of neuroscience.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267740655840,"sku":null,"price":320.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/6c431bd0-5652-4e60-8cb5-5774a4a85dc8.png?v=1782903656"},{"product_id":"na-selank-10mg","title":"NA Selank 10mg","description":"\u003cp\u003e\u003cspan\u003eNA Selank is the deamidated structure of Selank, primarily associated with the GABAergic system and neuropeptide signaling. Its effects are concentrated in mood regulation and maintenance of neural homeostasis. By influencing neurotransmitter balance and central regulatory pathways, its mechanisms hold significant importance in neurobehavioral, stress response, and neuromodulation research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e \u003c\/div\u003e\n\u003cdiv\u003eThe peptide will be provided as lyophilized powder to ensure maximum stability.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eWhat is NA Selank?\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eNA Selank is the deamidated structure of Selank, primarily associated with the GABAergic system and neuropeptide signaling. Its effects are concentrated in mood regulation and maintenance of neural homeostasis. By influencing neurotransmitter balance and central regulatory pathways, its mechanisms hold significant importance in neurobehavioral, stress response, and neuromodulation research.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e","brand":"我的商店","offers":[{"title":"Default Title","offer_id":53267776307424,"sku":null,"price":60.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0813\/1759\/3312\/files\/763e850f-4d4a-46c4-bd8e-a2941b49d9de.png?v=1782903806"}],"url":"https:\/\/zqzaq0-p8.myshopify.com\/collections\/the-highest-quality-peptides.oembed","provider":"COCER      PEPTIOES","version":"1.0","type":"link"}